ClinicalTrials.gg
CompletedNCT01186744Updated Dec 26, 2018Results posted

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of CP-690,550 and CP-690,550 in Psoriasis, sponsored by Pfizer. Completed at 87 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
6th of 19
666 · median 135
Started
2010
with 2 others
Phase 3
9 of 19
1 open now
Registered
4th of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 4th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period; 2) evaluate the regain of efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) following 4 -16 weeks of CP 690,550 treatment withdrawal and subsequent re treatment; and 3) evaluate the safety and tolerability of CP 690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

03

Conditions studied

  • Psoriasis

Keywords

  • OPT Retreatment
  • OPT
  • chronic
  • moderate
  • severe
  • treatment
  • safety
  • treatment withdrawal
  • retreatment
  • retreatment withdrawal
  • CP-690,550
  • Psoriasis Vulgaris
  • Plaque Psoriasis
  • tofacitinib
  • Xeljanz
  • nail psoriasis
  • Jak-inhibitor
  • oral treatment
  • Pruritus
  • Itch
  • DLQI
  • rebound
  • intermittent
  • retreat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug;
  • Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND Physician's Global Assessment (PGA) score of 3 (moderate) or 4 (severe); Psoriasis covering at least 10% of body surface area;
  • No evidence of active or latent or inadequately treated infection with Tuberculosis or other serious infections.

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug induced forms of psoriasis;
  • Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (Psoralen Ultraviolet A; Ultraviolet B).
  • Any uncontrolled significant medical condition.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (actual)

Study arms

  • Experimental
    Active Treatment (10 mg) BID / Placebo BID

    Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks

    Drug: CP-690,550

  • Experimental
    Active Treatment (10 mg) BID

    Continuous active treatment (CP-690,550) for 56 weeks

    Drug: CP-690,550

  • Experimental
    Active Treatment (5 mg) BID / Placebo BID

    Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks

    Drug: CP-690,550

  • Experimental
    Active Treatment (5 mg) BID

    Continuous active treatment (CP-690,550) for 56 weeks

    Drug: CP-690,550

Interventions

  • 10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design

  • 10 mg oral BID

  • 5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design

  • 5 mg oral BID

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.

    Time frame: Weeks 4, 8 12, and 16 (Period B)

  2. Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  3. Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  4. Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

Secondary outcomes

  1. Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)

    The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  2. Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)

    The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  3. Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)

    PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  4. Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

    Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  5. Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

    Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  6. Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)

    The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

    Time frame: Weeks 4 and 8 (Period B)

  7. Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)

    The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  8. Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)

    Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.

    Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)

  9. Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)

    Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)

  10. Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Weeks 4, 8, and 16 (Period C)

  11. Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Weeks 4, 8, and 16 (Period C)

  12. Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  13. Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  14. Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  15. Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  16. Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  17. Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)

    PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Weeks 4, 8, and 16 (Period C)

  18. Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

    PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  19. Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)

    PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  20. Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)

    PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

    Time frame: Weeks 4, 8, and 16 (Period C)

  21. Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  22. Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  23. Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  24. Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)

    Baseline defined as the last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  25. Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

    Baseline defined as the last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  26. Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

    Baseline was defined as the last observation until first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  27. Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  28. Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  29. Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

    Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  30. Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

    Baseline defined as the last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  31. Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

    Baseline defined as the last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  32. Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

    Baseline defined as the last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  33. Mean PASI Score During Initial CP-690,550 Treatment (Period A)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  34. Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  35. Mean PASI Score During the CP-690,550 Re-Treatment (Period C)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  36. Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  37. Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  38. Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  39. Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  40. Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  41. Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  42. Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  43. Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  44. Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

    Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  45. Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A

    PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  46. Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A

    PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  47. Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A

    PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  48. Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  49. Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  50. Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  51. Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)

    PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  52. Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  53. Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)

    PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, and 16 (Period C)

  54. Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  55. Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  56. Mean ISI Score During the CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  57. Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  58. Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-B defined as the last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  59. Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  60. Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  61. Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  62. Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  63. Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  64. Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  65. Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, and 16 (Period C)

  66. ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  67. Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  68. ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, and 16 (Period C)

  69. Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, and 16 (Period C)

  70. ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  71. Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  72. ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, and 16 (Period C)

  73. Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)

    The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

    Time frame: Weeks 4, 8, and 16 (Period C)

  74. Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  75. Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  76. Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  77. Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  78. Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  79. Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  80. Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  81. Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  82. Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  83. Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  84. Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  85. Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  86. Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  87. Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  88. Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Weeks 4, 8, and 16 (Period C)

  89. Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  90. Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  91. Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  92. Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.

    Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)

  93. Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  94. Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  95. Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, and 16 (Period C)

  96. Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

    The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

    Time frame: Weeks 4, 8, and 16 (Period C)

  97. Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 24 (Period A)

  98. Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 56 (Period C)

  99. Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

    Time frame: Week 24 (Period A)

  100. Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

    Time frame: Week 56 (Period C)

  101. Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 24 (Period A)

  102. Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

    Time frame: Baseline and Week 56 (Period C)

  103. Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Week 24 (Period A)

  104. Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

    The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Week 56 (Period C)

  105. Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe

    Time frame: Baseline and Weeks 4, 8, 16 and 24 (Period A)

  106. Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.

    Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)

  107. Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  108. Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  109. Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

    Time frame: Baseline and Weeks 4, 8, and 16 (Period C)

  110. Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B

    The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  111. Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  112. Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and Week 56 (Period C)

  113. Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Week 24 (Period A)

  114. Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Week 56 (Period C)

  115. Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

    Time frame: Baseline and Week 24 (Period A)

  116. Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

    Time frame: Baseline and Week 56 (Period C)

  117. Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-A defined as the last observation up to first dosing date in Period A.

    Time frame: Week 24 (Period A)

  118. Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-C defined as the last observation up to first dosing date in Period C.

    Time frame: Week 56 (Period C)

  119. Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)

    Time frame: Weeks 4, 8, 16, and 24 (Period A)

  120. Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)

    Time frame: Weeks 4, 8, 12, and 16 (Period B)

  121. Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)

    Time frame: Weeks 4, 8, and 16 (Period C)

07

Results

Posted Jun 4, 2014
Limitations and caveats
Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.

Participant flow

Participant flow — Overall Study
MilestoneCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mgCP-690,550 5 mg/Placebo/CP-690,550 5 mgCP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mgCP-690,550 10 mg / Placebo / CP-690,550 10 mg
Started218157318245133
Completed105257039107
Not completed208152612626
Withdrew: Lack of efficacy156990225
Withdrew: Protocol violation120112
Withdrew: Lost to follow-up15162114
Withdrew: Screen failure110100
Withdrew: Withdrawal by subject14102506
Withdrew: Study terminated by sponsor100000
Withdrew: Other9101215
Withdrew: Adverse event10141014
Withdrew: Death100000

Outcome measures

PrimaryPercentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.

Time frame:
Weeks 4, 8 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)
percentage of participantsCP-690,550 5 mg (Period B)Placebo for CP-690,550 5 mg (Period B)CP-690,550 10 mg (Period B)Placebo for 10 mg CP-690,550
Week 490.3 (72.9 to 96.8)63.4 (52.0 to 72.8)91.1 (78.0 to 96.6)61.4 (52.5 to 69.1)
Week 870.3 (50.6 to 83.3)36.2 (25.8 to 46.7)86.6 (72.5 to 93.7)39.6 (31.2 to 47.9)
Week 1263.2 (43.4 to 77.7)32.4 (22.4 to 42.7)77.2 (61.7 to 87.0)33.4 (25.4 to 41.5)
Week 1656.2 (36.7 to 71.8)23.3 (14.7 to 33.1)62.3 (45.8 to 75.0)26.1 (18.8 to 33.9)
Statistical analysis
  • CP-690,550 5 mg (Period B) vs Placebo for CP-690,550 5 mg (Period B) · Log Rank · p = 0.0008
  • CP-690,550 10 mg (Period B) vs Placebo for 10 mg CP-690,550 · Log Rank · p = <0.0001
PrimaryPercentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for CP-690,550 5 mg (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550
Week 480.6 (61.9 to 90.8)57.3 (45.9 to 67.2)80.0 (65.1 to 89.1)52.3 (43.4 to 60.4)
Week 867.7 (48.4 to 81.2)34.4 (24.2 to 44.8)80.0 (65.1 to 89.1)32.5 (24.6 to 40.6)
Week 1260.6 (41.1 to 75.4)26.7 (17.6 to 36.8)66.3 (50.4 to 78.1)23.8 (16.8 to 31.4)
Week 1649.9 (31.0 to 66.2)22.9 (14.4 to 32.6)63.9 (48.0 to 76.1)18.0 (11.9 to 25.2)
Statistical analysis
  • CP-690,550 5 mg BID (Period B) vs Placebo for CP-690,550 5 mg (Period B) · Log Rank · p = 0.0027
  • CP-690,550 10 mg BID (Period B) vs Placebo for 10 mg CP-690,550 · Log Rank · p = <0.0001
PrimaryPercentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline50.00 (0.00 to 100.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 4100.00 (100.00 to 100.00)13.16 (2.41 to 23.91)0.00 (0.00 to 0.00)40.68 (28.14 to 53.21)
Week 8100.00 (100.00 to 100.00)31.58 (16.80 to 46.36)0.00 (0.00 to 0.00)49.15 (36.40 to 61.91)
Week 1650.00 (0.00 to 100.00)31.58 (16.80 to 46.36)0.00 (0.00 to 0.00)50.85 (38.09 to 63.60)
PrimaryPercentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline23.08 (0.17 to 45.98)5.17 (0.0 to 10.87)6.67 (0.0 to 19.29)7.14 (2.04 to 12.24)
Week 423.08 (0.17 to 45.98)25.86 (14.59 to 37.13)33.33 (9.48 to 57.19)51.02 (41.12 to 60.92)
Week 830.77 (5.68 to 55.86)39.66 (27.07 to 52.24)40.0 (15.21 to 64.79)55.10 (45.25 to 64.95)
Week 1630.77 (5.68 to 55.86)41.38 (28.70 to 54.05)53.33 (28.09 to 78.58)48.98 (39.08 to 58.88)
SecondaryMedian Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)

The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Median · weeks
Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)
weeksCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)24.3 (24.1 to 24.6)8.7 (8.1 to 15.4)
SecondaryMedian Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)

The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Median · weeks
Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)
weeksCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)24.1 (16.6 to 24.4)8.1 (NA to NA)
SecondaryPercentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)

PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Week 412.69 (9.10 to 16.27)21.19 (16.82 to 25.57)
Week 818.73 (14.53 to 22.93)19.40 (15.17 to 23.64)
Week 1618.13 (13.98 to 22.28)13.13 (9.52 to 16.75)
Week 2410.88 (7.52 to 14.23)10.15 (6.92 to 13.38)
SecondaryPercentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg (Period B)Placebo for 5 mg CP-690,550 (Period B)CP-690,550 10 mg (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4100.0 (100.0 to 100.0)90.0 (81.0 to 94.9)100.0 (100.0 to 100.0)85.9 (78.6 to 90.9)
Week 896.7 (78.6 to 99.5)72.0 (60.6 to 80.6)97.7 (84.6 to 99.7)68.4 (59.5 to 75.7)
Week 1296.7 (78.6 to 99.5)58.8 (47.0 to 68.8)93.0 (79.9 to 97.7)58.5 (49.4 to 66.6)
Week 1692.3 (72.1 to 98.0)32.8 (16.3 to 50.4)93.0 (79.9 to 97.7)42.9 (30.5 to 54.6)
SecondaryMedian Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)

Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Median · weeks
Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)
weeksCP-690,550 5 mg (Period B)Placebo for 5 mg CP-690,550 (Period B)CP-690,550 10 mg (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)NA (NA to NA)16.4 (12.6 to NA)NA (NA to NA)16.1 (14.1 to NA)
SecondaryPercentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)

The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame:
Weeks 4 and 8 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 (Period B)CP-690,550 10 mg (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,128)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 8 (n=31,70,43,106)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Overall (n=31,82,44,132)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
SecondaryPercentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)

The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 (Period B)CP-690,550 10 mg (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,128)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 8 (n=31,70,43,106)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 12 (n=30,53,43,87)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)1.15 (-3.39 to 1.09)
Week 16 (n=28,45,38,72)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Overall (n=31,82,45,132)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.76 (0.00 to 0.00)
SecondaryPercentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)

Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.

Time frame:
Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4100.00 (100.0 to 100.0)90.0 (81.0 to 94.9)100.0 (100.0 to 100.0)85.9 (78.6 to 90.9)
Week 896.7 (78.6 to 99.5)72.0 (60.6 to 80.6)97.7 (84.6 to 99.7)68.4 (59.5 to 75.7)
Week 1296.7 (78.6 to 99.5)58.8 (47.0 to 68.8)93.0 (79.9 to 97.7)58.4 (49.3 to 66.5)
Week 1692.3 (72.1 to 98.0)32.8 (16.3 to 50.4)93.0 (79.9 to 97.7)43.5 (31.0 to 55.3)
SecondaryMedian Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)
Time frame:
Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Median · weeks
Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)
weeksCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)NA (NA to NA)16.4 (12.6 to NA)NA (NA to NA)16.1 (14.1 to NA)
SecondaryPercentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 414.3 (2.1 to 66.6)7.7 (3.0 to 19.2)14.3 (2.1 to 66.6)37.0 (27.6 to 48.5)
Week 828.6 (8.0 to 74.2)32.3 (21.2 to 47.3)42.9 (16.3 to 82.8)48.5 (38.2 to 60.0)
Week 1664.3 (22.0 to 98.6)100.0 (NA to NA)42.9 (16.3 to 82.8)57.2 (46.2 to 68.8)
SecondaryMedian Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C16.4 (8.6 to NA)16.4 (16.1 to 17.3)NA (NA to NA)12.4 (7.6 to NA)
SecondaryPercentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 414.29 (0.00 to 40.21)7.69 (0.45 to 14.93)14.29 (0.00 to 40.21)37.04 (26.52 to 47.55)
Week 828.57 (0.00 to 62.04)28.85 (16.53 to 41.16)42.86 (6.2 to 79.52)41.98 (31.23 to 52.72)
Week 1628.57 (0.00 to 62.04)21.15 (10.05 to 32.25)42.86 (6.20 to 79.52)41.98 (31.23 to 52.72)
SecondaryMedian Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)4.5 (4.3 to 4.7)16.4 (16.1 to 17.3)NA (NA to NA)8.1 (5.9 to 16.1)
SecondaryMedian Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C
Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C16.3 (16.1 to 16.4)16.1 (8.4 to 16.6)13.1 (6.0 to NA)8.1 (5.0 to 16.1)
SecondaryPercentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 47.85 (4.96 to 10.75)22.39 (17.92 to 26.85)
Week 823.87 (19.27 to 28.46)50.45 (45.09 to 55.80)
Week 1638.07 (32.84 to 43.30)60.60 (55.36 to 65.83)
Week 2438.97 (33.72 to 44.23)59.40 (54.14 to 64.66)
SecondaryPercentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 487.10 (7.94 to 39.43)63.41 (0.00 to 0.00)86.67 (14.29 to 40.24)59.40 (0.00 to 0.00)
Week 870.97 (17.83 to 55.81)34.15 (0.00 to 0.00)86.67 (35.40 to 61.24)38.35 (0.00 to 0.00)
Week 1267.74 (18.02 to 56.49)30.49 (0.00 to 0.00)77.78 (29.38 to 58.51)33.83 (0.00 to 0.00)
Week 1664.52 (20.89 to 59.36)24.39 (0.00 to 0.00)62.22 (18.32 to 50.49)27.82 (0.00 to 0.00)
SecondaryPercentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)

PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 470.37 (53.15 to 87.59)34.67 (23.90 to 45.44)73.81 (60.51 to 87.11)60.83 (52.10 to 69.57)
Week 862.96 (44.75 to 81.18)48.00 (36.69 to 59.31)66.67 (52.41 to 80.92)68.33 (60.01 to 76.66)
Week 1655.56 (36.81 to 74.30)45.33 (34.07 to 56.60)69.05 (55.07 to 83.03)61.67 (52.97 to 70.37)
SecondaryPercentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 414.20 (10.44 to 17.96)37.91 (32.72 to 43.11)
Week 830.51 (25.55 to 35.47)54.03 (48.69 to 59.37)
Week 1637.16 (31.95 to 42.37)58.81 (53.54 to 64.08)
Week 2437.16 (31.95 to 42.37)55.22 (49.90 to 60.55)
SecondaryPercentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)

PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 477.42 (1.90 to 38.30)57.32 (0.00 to 0.00)77.78 (14.84 to 44.48)48.12 (0.00 to 0.00)
Week 874.19 (22.81 to 59.73)32.93 (0.00 to 0.00)82.22 (35.40 to 62.88)33.08 (0.00 to 0.00)
Week 1270.97 (24.21 to 61.62)28.05 (0.00 to 0.00)66.67 (24.68 to 56.09)26.32 (0.00 to 0.00)
Week 1658.06 (10.11 to 49.92)28.05 (0.00 to 0.00)62.22 (25.40 to 56.94)21.05 (0.00 to 0.00)
SecondaryPercentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)

PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 462.96 (44.75 to 81.18)40.00 (28.91 to 51.09)61.90 (47.22 to 76.59)59.17 (50.37 to 67.96)
Week 862.96 (44.75 to 81.18)49.33 (38.02 to 60.65)54.76 (39.71 to 69.81)63.33 (54.71 to 71.96)
Week 1655.56 (36.81 to 74.30)49.33 (38.02 to 60.65)59.52 (44.68 to 74.37)55.00 (46.10 to 63.90)
SecondaryMean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · percent psoriatic BSA
Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)
percent psoriatic BSACP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline (n=331,335)27.5 ± 0.927.2 ± 0.9
Week 4 (n=326,331)22.3 ± 0.918.1 ± 0.8
Week 8 (n=322,323)17.2 ± 0.912.1 ± 0.8
Week 16 (n=311,306)13.3 ± 0.88.1 ± 0.7
Week 24 (n=277,279)12.0 ± 0.86.4 ± 0.7
SecondaryMean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · percent psoriatic BSA
Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)
percent psoriatic BSACP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline (n=31,82,45,133)1.9 ± 0.43.8 ± 0.82.0 ± 0.32.7 ± 0.4
Week 4 (n=30,82,43,128)1.9 ± 0.46.1 ± 0.81.8 ± 0.46.8 ± 0.9
Week 8 (n=30,70,43,104)2.2 ± 0.47.7 ± 1.22.0 ± 0.48.7 ± 1.2
Week 12 (n=28,53,42,84)2.0 ± 0.47.2 ± 1.02.3 ± 0.56.2 ± 0.9
Week 16 (n=28,45,38,70)2.2 ± 0.56.0 ± 0.92.6 ± 0.76.0 ± 0.8
SecondaryMean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · percent psoriatic BSA
Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)
percent psoriatic BSACP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline (n=27,75,42,120)2.3 ± 0.511.4 ± 1.33.0 ± 0.812.0 ± 1.2
Week 4 (n=27,74,42,119)2.1 ± 0.410.6 ± 1.73.1 ± 0.97.2 ± 0.9
Week 8 (n=26,72,41,118)2.5 ± 0.59.0 ± 1.63.3 ± 1.06.1 ± 0.8
Week 16 (n=23,67,39,101)2.9 ± 0.57.1 ± 1.23.7 ± 1.34.5 ± 0.8
SecondaryMean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)

Baseline defined as the last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · percent change in psoriatic BSA
Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)
percent change in psoriatic BSACP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 4 (n=326,331)-5.3 ± 0.5-9.0 ± 0.7
Week 8 (n=322,323)-10.4 ± 0.7-14.5 ± 0.8
Week 16 (n=311,306)-14.4 ± 0.8-18.5 ± 0.9
Week 24 (n=277,279)-15.2 ± 0.9-19.4 ± 0.9
SecondaryMean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)

Baseline defined as the last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · percent change in psoriatic BSA
Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)
percent change in psoriatic BSACP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,128)0.0 ± 0.42.3 ± 0.9-0.3 ± 0.34.1 ± 0.6
Week 8 (n=30,70,43,104)0.3 ± 0.44.1 ± 0.9-0.1 ± 0.46.3 ± 0.9
Week 12 (n=28,53,42,84)0.1 ± 0.54.8 ± 1.00.3 ± 0.64.7 ± 0.7
Week 16 (n=28,45,38,70)0.3 ± 0.53.7 ± 0.70.5 ± 0.74.5 ± 0.7
SecondaryMean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)

Baseline was defined as the last observation until first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · percent change in psoriatic BSA
Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)
percent change in psoriatic BSACP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 4 (n=27,74,42,119)-0.2 ± 0.3-1.0 ± 1.00.1 ± 0.9-4.9 ± 0.8
Week 8 (n=26,72,41,118)0.1 ± 0.5-2.3 ± 1.00.3 ± 0.9-5.5 ± 0.8
Week 16 (n=23,67,39,101)0.5 ± 0.6-4.0 ± 1.10.6 ± 1.2-6.8 ± 0.8
SecondaryMean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · percent psoriatic BSA
Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)
percent psoriatic BSACP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Head/Neck, Baseline (n=331,335)28.7 ± 1.2525.9 ± 1.17
Head/Neck, Week 4 (n=326,331)20.5 ± 1.2014.3 ± 1.04
Head/Neck, Week 8 (n=322,323)14.8 ± 1.069.7 ± 0.96
Head/Neck, Week 16 (n=311,306)12.6 ± 1.057.5 ± 0.88
Head/Neck, Week 24 (n=277,279)12.8 ± 1.176.3 ± 0.89
Upper limbs, Baseline (n=331,335)26.5 ± 1.0426.2 ± 1.06
Upper limbs, Week 4 (n=326,331)21.8 ± 1.0217.3 ± 0.91
Upper limbs, Week 8 (n=322,323)17.0 ± 0.9511.7 ± 0.83
Upper Limbs, Week 16 (n=311,306)13.6 ± 0.928.0 ± 0.70
Upper limbs, Week 24 (n=277,279)12.2 ± 0.986.5 ± 0.65
Trunk, Baseline (n=331,335)26.0 ± 1.2325.9 ± 1.18
Trunk, Week 4 (n=326,331)20.8 ± 1.1617.2 ± 1.02
Trunk, Week 8 (n=322,323)16.5 ± 1.1111.4 ± 0.94
Trunk, Week 16 (n=311,306)13.5 ± 1.058.5 ± 0.95
Trunk, Week 24 (n=277,279)12.5 ± 1.056.9 ± 0.85
Lower limbs, Baseline (n=331,335)28.7 ± 1.1428.9 ± 1.12
Lower limbs, Week 4 (n=326,331)24.1 ± 1.1320.2 ± 0.99
Lower limbs, Week 8 (n=322,323)18.5 ± 1.0513.4 ± 0.93
Lower limbs, Week 16 (n=311,306)13.1 ± 0.957.9 ± 0.79
Lower limbs, Week 24 (n=277,279)11.3 ± 0.906.1 ± 0.71
SecondaryMean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · percent psoriatic BSA
Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)
percent psoriatic BSACP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Head/Neck, Baseline (n=31,82,45,133)4.2 ± 1.533.3 ± 0.790.9 ± 0.342.8 ± 0.70
Head/Neck, Week 4 (n=30,82,43,128)4.1 ± 1.4411.3 ± 1.991.5 ± 0.4412.2 ± 1.59
Head/Neck, Week 8 (n=30,70,43,104)4.8 ± 1.8013.0 ± 2.341.5 ± 0.4615.1 ± 1.97
Head/Neck, Week 12 (n=28,53,42,84)3.8 ± 1.0013.5 ± 2.962.8 ± 0.7211.5 ± 2.03
Head/Neck, Week 16 (n=28,45,38,70)3.8 ± 1.199.2 ± 2.112.3 ± 0.809.6 ± 1.76
Upper limbs, Baseline (n=31,82,45,133)2.1 ± 0.425.1 ± 1.003.1 ± 0.553.1 ± 0.50
Upper limbs, Week 4 (n=30,82,43,128)2.4 ± 0.487.5 ± 1.193.0 ± 0.557.6 ± 0.97
Upper limbs, Week 8 (n=30,70,43,104)2.8 ± 0.588.9 ± 1.413.6 ± 0.688.9 ± 1.25
Upper limbs, Week 12 (n=28,53,42,84)3.1 ± 0.598.8 ± 1.383.3 ± 0.626.6 ± 1.00
Upper limbs, Week 16 (n=28,45,38,70)3.2 ± 0.706.5 ± 1.133.5 ± 0.666.9 ± 1.28
Trunk, Baseline (n=31,82,45,133)1.6 ± 0.523.2 ± 0.881.5 ± 0.532.6 ± 0.59
Trunk, Week 4 (n=30,82,43,128)1.8 ± 0.535.1 ± 1.001.6 ± 0.536.0 ± 1.05
Trunk, Week 8 (n=30,70,43,104)1.9 ± 0.567.4 ± 1.731.5 ± 0.377.9 ± 1.29
Trunk, Week 12 (n=28,53,42,84)1.7 ± 0.614.4 ± 0.671.4 ± 0.395.3 ± 1.04
Trunk, Week 16 (n=28,45,38,70)2.1 ± 0.744.8 ± 0.901.8 ± 0.915.5 ± 1.05
Lower limbs, Baseline (n=31,82,45,133)1.3 ± 0.373.8 ± 1.022.1 ± 0.442.4 ± 0.49
Lower limbs, Week 4 (n=30,82,43,128)1.2 ± 0.334.9 ± 0.751.4 ± 0.385.7 ± 0.90
Lower limbs, Week 8 (n=30,70,43,104)1.5 ± 0.366.1 ± 1.071.7 ± 0.537.5 ± 1.30
Lower limbs, Week 12 (n=28,53,42,84)1.2 ± 0.357.0 ± 1.242.4 ± 0.805.4 ± 0.95
Lower limbs, Week 16 (n=28,45,38,70)1.4 ± 0.426.0 ± 1.303.0 ± 1.035.1 ± 0.78
SecondaryMean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · percent psoriatic BSA
Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)
percent psoriatic BSACP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Head/Neck, Baseline (n=27,75,42,120)4.0 ± 1.2318.6 ± 2.622.0 ± 0.6118.3 ± 1.95
Head/Neck, Week 4 (n=27,74,42,119)3.6 ± 1.3312.5 ± 2.092.9 ± 0.767.5 ± 1.12
Head/Neck, Week 8 (n=26,72,41,118)3.9 ± 1.259.5 ± 2.013.3 ± 1.086.3 ± 1.02
Head/Neck, Week 16 (n=23,67,39,101)4.6 ± 1.509.8 ± 1.971.4 ± 0.466.1 ± 1.31
Upper limbs, Baseline (n=27,75,42,120)3.2 ± 0.7212.5 ± 1.733.6 ± 0.6313.2 ± 1.40
Upper limbs, Week 4 (n=27,74,42,119)3.4 ± 0.8211.1 ± 1.924.1 ± 0.908.4 ± 1.23
Upper limbs, Week 8 (n=26,72,41,118)4.1 ± 0.998.9 ± 1.833.7 ± 0.926.7 ± 0.97
Upper limbs, Week 16 (n=23,67,39,101)4.0 ± 1.027.0 ± 1.334.6 ± 1.245.3 ± 1.02
Trunk, Baseline (n=27,75,42,120)2.2 ± 0.7710.9 ± 1.732.0 ± 0.8511.1 ± 1.35
Trunk, Week 4 (n=27,74,42,119)2.0 ± 0.6811.1 ± 2.333.2 ± 1.726.7 ± 1.10
Trunk, Week 8 (n=26,72,41,118)2.4 ± 0.7310.2 ± 2.163.5 ± 1.765.9 ± 1.15
Trunk, Week 16 (n=23,67,39,101)3.0 ± 0.967.1 ± 1.544.7 ± 2.344.8 ± 1.16
Lower limbs, Baseline (n=27,75,42,120)1.4 ± 0.449.4 ± 1.213.7 ± 1.1510.4 ± 1.27
Lower limbs, Week 4 (n=27,74,42,119)1.1 ± 0.279.5 ± 1.812.6 ± 0.956.9 ± 1.06
Lower limbs, Week 8 (n=26,72,41,118)1.4 ± 0.388.0 ± 1.733.0 ± 1.105.8 ± 0.92
Lower limbs, Week 16 (n=23,67,39,101)1.8 ± 0.456.5 ± 1.263.0 ± 1.333.5 ± 0.64
SecondaryMean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)

Baseline defined as the last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · percent change in psoriatic BSA
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)
percent change in psoriatic BSACP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Head/Neck, Week 4 (n=326,331)-7.9 ± 0.71-11.7 ± 0.86
Head/Neck, Week 8 (n=322,323)-13.8 ± 0.98-16.0 ± 1.04
Head/Neck, Week 16 (n=311,306)-15.4 ± 1.13-17.9 ± 1.07
Head/Neck, Week 24 (n=277,279)-14.9 ± 1.21-18.6 ± 1.12
Upper limbs, Week 4 (n=326,331)-4.9 ± 0.58-8.8 ± 0.80
Upper limbs, Week 8 (n=322,323)-9.7 ± 0.77-14.1 ± 0.92
Upper limbs, Week 16 (n=311,306)-13.1 ± 0.89-17.4 ± 1.03
Upper limbs, Week 24 (n=277,279)-14.2 ± 0.98-18.5 ± 1.01
Trunk, Week 4 (n=326,331)-5.5 ± 0.67-8.6 ± 0.86
Trunk, Week 8 (n=322,323)-9.9 ± 0.87-13.8 ± 1.03
Trunk, Week 16 (n=311,306)-12.9 ± 0.98-16.9 ± 1.17
Trunk, Week 24 (n=277,279)-13.4 ± 1.12-17.8 ± 1.12
Lower limbs, Week 4 (n=326,331)-4.8 ± 0.57-8.6 ± 0.85
Lower limbs, Week 8 (n=322,323)-10.4 ± 0.82-14.8 ± 0.99
Lower limbs, Week 16 (n=311,306)-15.9 ± 1.04-20.3 ± 1.10
Lower limbs, Week 24 (n=277,279)-17.1 ± 1.09-21.2 ± 1.07
SecondaryMean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)

Baseline defined as the last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · percent psoriatic BSA
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)
percent psoriatic BSACP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Head/Neck, Week 4 (n=30,82,43,128)-0.3 ± 0.988.0 ± 1.490.7 ± 0.449.3 ± 1.53
Head/Neck, Week 8 (n=30,70,43,104)0.4 ± 1.4110.0 ± 1.870.6 ± 0.5012.8 ± 1.86
Head/Neck, Week 12 (n=28,53,42,84)-0.9 ± 1.5811.8 ± 2.711.8 ± 0.6910.4 ± 1.95
Head/Neck, Week 16 (n=28,45,38,70)-0.8 ± 1.427.9 ± 1.701.2 ± 0.758.3 ± 1.66
Upper limbs, Week 4 (n=30,82,43,128)0.4 ± 0.332.3 ± 1.14-0.2 ± 0.294.5 ± 0.76
Upper limbs, Week 8 (n=30,70,43,104)0.8 ± 0.474.1 ± 0.990.4 ± 0.546.2 ± 0.96
Upper limbs, Week 12 (n=28,53,42,84)1.0 ± 0.514.8 ± 1.140.4 ± 0.504.7 ± 0.86
Upper limbs, Week 16 (n=28,45,38,70)1.1 ± 0.552.7 ± 0.750.6 ± 0.464.9 ± 0.95
Trunk, Week 4 (n=30,82,43,128)0.1 ± 0.501.9 ± 1.170.0 ± 0.513.3 ± 0.74
Trunk, Week 8 (n=30,70,43,104)0.3 ± 0.544.0 ± 1.34-0.2 ± 0.565.6 ± 0.97
Trunk, Week 12 (n=28,53,42,84)0.0 ± 0.682.9 ± 0.75-0.2 ± 0.633.8 ± 0.75
Trunk, Week 16 (n=28,45,38,70)0.4 ± 0.733.3 ± 0.810.0 ± 1.093.9 ± 0.71
Lower limbs, Week 4 (n=30,82,43,128)-0.2 ± 0.421.1 ± 0.92-0.7 ± 0.393.2 ± 0.68
Lower limbs, Week 8 (n=30,70,43,104)0.2 ± 0.432.7 ± 0.83-0.5 ± 0.665.3 ± 0.98
Lower limbs, Week 12 (n=28,53,42,84)-0.1 ± 0.474.6 ± 1.190.3 ± 0.843.9 ± 0.84
Lower limbs, Week 16 (n=28,45,38,70)0.0 ± 0.513.3 ± 0.940.7 ± 0.863.7 ± 0.76
SecondaryMean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)

Baseline defined as the last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · percent psoriatic BSA
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)
percent psoriatic BSACP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Head/Neck, Week 4 (n=27,74,42,119)-0.3 ± 0.92-6.4 ± 1.400.9 ± 0.81-10.8 ± 1.53
Head/Neck, Week 8 (n=26,72,41,118)0.0 ± 1.07-8.6 ± 1.681.2 ± 0.91-10.9 ± 1.51
Head/Neck, Week 16 (n=23,67,39,101)0.4 ± 1.41-8.1 ± 2.04-0.7 ± 0.77-11.6 ± 1.84
Upper limbs, Week 4 (n=27,74,42,119)0.1 ± 0.26-1.6 ± 0.900.5 ± 0.69-4.9 ± 0.94
Upper limbs, Week 8 (n=26,72,41,118)0.8 ± 0.50-3.0 ± 0.850.1 ± 0.53-6.3 ± 1.11
Upper limbs, Week 16 (n=23,67,39,101)0.7 ± 0.97-5.0 ± 1.151.0 ± 0.99-7.6 ± 1.20
Trunk, Week 4 (n=27,74,42,119)-0.2 ± 0.200.1 ± 1.121.3 ± 1.87-4.6 ± 0.88
Trunk, Week 8 (n=26,72,41,118)0.1 ± 0.43-1.1 ± 1.041.5 ± 1.92-4.8 ± 0.88
Trunk, Week 16 (n=23,67,39,101)0.7 ± 0.82-4.1 ± 1.442.7 ± 2.46-5.6 ± 1.02
Lower limbs, Week 4 (n=27,74,42,119)-0.3 ± 0.36-0.1 ± 1.44-1.1 ± 0.93-3.6 ± 0.97
Lower limbs, Week 8 (n=26,72,41,118)-0.1 ± 0.52-1.3 ± 1.50-0.7 ± 0.78-4.3 ± 0.85
Lower limbs, Week 16 (n=23,67,39,101)0.2 ± 0.60-2.3 ± 1.15-0.9 ± 1.14-6.1 ± 0.93
SecondaryMean PASI Score During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean PASI Score During Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline (n=331,335)21.1 ± 0.520.9 ± 0.4
Week 4 (n=326,331)13.5 ± 0.510.4 ± 0.4
Week 8 (n=322,323)10.1 ± 0.46.5 ± 0.4
Week 16 (n=311,307)8.1 ± 0.45.0 ± 0.4
Week 24 (n=277,279)7.6 ± 0.44.4 ± 0.4
SecondaryMean PASI Score During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline (n=31,82,45,133)1.6 ± 0.21.8 ± 0.21.7 ± 0.21.5 ± 0.1
Week 4 (n=30,82,43,128)2.0 ± 0.35.0 ± 0.61.8 ± 0.35.3 ± 0.6
Week 8 (n=30,70,43,104)2.4 ± 0.46.5 ± 0.72.0 ± 0.46.8 ± 0.7
Week 12 (n=28,53,42,84)2.3 ± 0.46.4 ± 0.72.5 ± 0.45.6 ± 0.6
Week 16 (n=28,45,38,70)2.7 ± 0.55.5 ± 0.72.9 ± 0.55.5 ± 0.6
SecondaryMean PASI Score During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean PASI Score During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline (n=27,75,42,120)2.7 ± 0.59.9 ± 0.93.4 ± 0.69.8 ± 0.8
Week 4 (n=27,74,42,119)2.5 ± 0.47.8 ± 1.03.3 ± 0.65.0 ± 0.5
Week 8 (n=26,72,41,118)2.6 ± 0.56.0 ± 0.93.2 ± 0.64.1 ± 0.5
Week 16 (n=23,67,39,101)2.9 ± 0.55.2 ± 0.83.5 ± 0.73.5 ± 0.5
SecondaryMean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 4 (n=326,331)-7.6 ± 0.4-10.5 ± 0.4
Week 8 (n=322,323)-11.1 ± 0.4-14.2 ± 0.5
Week 16 (n=311,307)-13.1 ± 0.5-15.8 ± 0.5
Week 24 (n=277,279)-13.4 ± 0.5-16.0 ± 0.5
SecondaryMean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)
scores on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,128)0.4 ± 0.23.3 ± 0.60.2 ± 0.23.8 ± 0.5
Week 8 (n=30,70,43,104)0.9 ± 0.44.9 ± 0.70.3 ± 0.35.4 ± 0.6
Week 12 (n=28,53,42,84)0.7 ± 0.44.8 ± 0.70.9 ± 0.44.5 ± 0.6
Week 16 (n=28,45,38,70)1.0 ± 0.54.1 ± 0.61.4 ± 0.44.4 ± 0.5
SecondaryMean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 4 (n=27,74,42,119)-0.2 ± 0.4-2.3 ± 0.7-0.1 ± 0.5-4.8 ± 0.6
Week 8 (n=26,72,41,118)0.0 ± 0.5-3.8 ± 0.7-0.2 ± 0.4-5.4 ± 0.6
Week 16 (n=23,67,39,101)0.1 ± 0.6-4.5 ± 0.9-0.0 ± 0.7-5.9 ± 0.6
SecondaryMean PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Erythema Head/Neck, Baseline (n=331,335)2.2 ± 0.12.2 ± 0.1
Erythema Head/Neck, Week 4 (n=326,331)1.4 ± 0.11.1 ± 0.1
Erythema Head/Neck, Week 8 (n=322,323)1.1 ± 0.10.7 ± 0.0
Erythema Head/Neck, Week 16 (n=311,307)1.0 ± 0.10.7 ± 0.1
Erythema Head/Neck, Week 24 (n=277,279)1.0 ± 0.10.6 ± 0.1
Induration Head/Neck, Baseline (n=331,335)2.0 ± 0.11.9 ± 0.1
Induration Head/Neck, Week 4 (n=326,331)1.2 ± 0.10.9 ± 0.1
Induration Head/Neck, Week 8 (n=322,323)0.9 ± 0.10.6 ± 0.0
Induration Head/Neck, Week 16 (n=311,307)0.8 ± 0.10.5 ± 0.0
Induration Head/Neck, Week 24 (n=277,279)0.8 ± 0.10.5 ± 0.0
Scaling Head/Neck, Baseline (n=331,335)2.2 ± 0.12.1 ± 0.1
Scaling Head/Neck, Week 4 (n=326,331)1.3 ± 0.11.0 ± 0.1
Scaling Head/Neck, Week 8 (n=322,323)1.0 ± 0.10.6 ± 0.0
Scaling Head/Neck, Week 16 (n=311,307)0.9 ± 0.10.6 ± 0.1
Scaling Head/Neck, Week 24 (n=277,279)0.9 ± 0.10.6 ± 0.1
Erythema Upper limbs, Baseline (n=331,335)2.8 ± 0.02.8 ± 0.0
Erythema Upper limbs, Week 4 (n=326,331)1.9 ± 0.01.6 ± 0.0
Erythema Upper limbs, Week 8 (n=322,323)1.6 ± 0.11.2 ± 0.0
Erythema Upper limbs, Week 16 (n=311,307)1.4 ± 0.11.1 ± 0.1
Erythema Upper limbs, Week 24 (n=277,279)1.4 ± 0.11.0 ± 0.1
Induration Upper limbs, Baseline (n=331,335)2.6 ± 0.02.6 ± 0.0
Induration Upper limbs, Week 4 (n=326,331)1.9 ± 0.01.5 ± 0.1
Induration Upper limbs, Week 8 (n=322,323)1.5 ± 0.11.1 ± 0.1
Induration Upper limbs, Week 16 (n=311,3071.4 ± 0.11.0 ± 0.1
Induration Upper limbs, Week 24 (n=277,279)1.4 ± 0.11.0 ± 0.1
Scaling Upper limbs, Baseline (n=331,335)2.7 ± 0.02.6 ± 0.0
Scaling Upper limbs, Week 4 (n=326,331)1.9 ± 0.01.5 ± 0.1
Scaling Upper limbs, Week 8 (n=322,323)1.5 ± 0.11.1 ± 0.1
Scaling Upper limbs, Week 16 (n=311,307)1.4 ± 0.11.0 ± 0.1
Scaling Upper limbs, Week 24 (n=277,279)1.4 ± 0.11.0 ± 0.1
Erythema Trunk, Baseline (n=331,335)2.9 ± 0.02.8 ± 0.0
Erythema Trunk, Week 4 (n=326,331)1.9 ± 0.11.6 ± 0.1
Erythema Trunk, Week 8 (n=322,323)1.6 ± 0.11.1 ± 0.1
Erythema Trunk, Week 16 (n=311,307)1.4 ± 0.10.9 ± 0.1
Erythema Trunk, Week 24 (n=277,279)1.4 ± 0.10.8 ± 0.1
Induration Trunk, Baseline (n=331,335)2.6 ± 0.02.6 ± 0.0
Induration Trunk, Week 4 (n=326,331)1.8 ± 0.11.4 ± 0.1
Induration Trunk, Week 8 (n=322,323)1.4 ± 0.10.9 ± 0.1
Induration Trunk, Week 16 (n=311,307)1.2 ± 0.10.8 ± 0.1
Induration Trunk, Week 24 (n=277,279)1.2 ± 0.10.7 ± 0.1
Scaling Trunk, Baseline (n=331,335)2.6 ± 0.02.5 ± 0.0
Scaling Trunk, Week 4 (n=326,331)1.7 ± 0.11.4 ± 0.1
Scaling Trunk, Week 8 (n=322,323)1.3 ± 0.10.9 ± 0.1
Scaling Trunk, Week 16 (n=311,307)1.2 ± 0.10.7 ± 0.1
Scaling Trunk, Week 24 (n=277,279)1.1 ± 0.10.7 ± 0.1
Erythema Lower limbs, Baseline (n=331,335)3.1 ± 0.03.1 ± 0.0
Erythema Lower limbs, Week 4 (n=326,331)2.2 ± 0.01.9 ± 0.1
Erythema Lower limbs, Week 8 (n=322,323)1.9 ± 0.11.4 ± 0.1
Erythema Lower limbs, Week 16 (n=311,307)1.5 ± 0.11.1 ± 0.1
Erythema Lower limbs, Week 24 (n=277,279)1.4 ± 0.11.0 ± 0.1
Induration Lower limbs, Baseline (n=331,335)2.9 ± 0.02.9 ± 0.0
Induration Lower limbs, Week 4 (n=326,331)2.1 ± 0.01.6 ± 0.1
Induration Lwer limbs, Week 8 (n=322,323)1.6 ± 0.11.2 ± 0.1
Induration Lower limbs, Week 16 (n=311,307)1.3 ± 0.10.9 ± 0.1
Induration Lower limbs, Week 24 (n=277,279)1.3 ± 0.10.9 ± 0.1
Scaling Lower limbs, Baseline (n=331,335)2.9 ± 0.02.9 ± 0.0
Scaling Lower limbs, Week 4 (n=326,331)2.0 ± 0.11.8 ± 0.1
Scaling Lower limbs, Week 8 (n=322,323)1.6 ± 0.11.2 ± 0.1
Scaling Lower limbs, Week 16 (n=311,307)1.3 ± 0.11.0 ± 0.1
Scaling Lower limbs, Week 24 (n=277,279)1.3 ± 0.11.0 ± 0.1
SecondaryMean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for CP-690,550 5 mg BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 (Period B)
Erythema Head/Neck, Baseline (n=31,82,45,133)0.5 ± 0.10.4 ± 0.10.3 ± 0.10.3 ± 0.0
Erythema Head/Neck, Week 4 (n=30,82,43,128)0.6 ± 0.11.1 ± 0.10.4 ± 0.11.1 ± 0.1
Erythema Head/Neck, Week 8 (n=30,70,43,104)0.7 ± 0.21.2 ± 0.10.3 ± 0.11.3 ± 0.1
Erythema Head/Neck, Week 12 (n=28,53,42,84)0.7 ± 0.21.1 ± 0.20.5 ± 0.11.1 ± 0.1
Erythema Head/Neck, Week 16 (n=28,45,38,70)0.7 ± 0.20.8 ± 0.10.5 ± 0.11.0 ± 0.1
Induration Head/Neck, Baseline (n=31,82,45,133)0.3 ± 0.10.4 ± 0.10.1 ± 0.10.2 ± 0.0
Induration Head/Neck, Week 4 (n=30,82,43,128)0.4 ± 0.10.9 ± 0.10.3 ± 0.10.9 ± 0.1
Induration Head/Neck, Week 8 (n=30,70,43,104)0.4 ± 0.11.0 ± 0.10.3 ± 0.11.1 ± 0.1
Induration Head/Neck, Week 12 (n=28,53,42,84)0.4 ± 0.10.9 ± 0.10.4 ± 0.10.9 ± 0.1
Induration Head/Neck, Week 16 (n=28,45,38,70)0.5 ± 0.10.7 ± 0.10.3 ± 0.10.8 ± 0.1
Scaling Head/Neck, Baseline (n=31,82,45,133)0.4 ± 0.10.4 ± 0.10.2 ± 0.10.3 ± 0.1
Scaling Head/Neck, Week 4 (n=30,82,43,128)0.4 ± 0.11.0 ± 0.10.3 ± 0.11.1 ± 0.1
Scaling Head/Neck, Week 8 (n=30,70,43,104)0.5 ± 0.11.1 ± 0.10.4 ± 0.11.3 ± 0.1
Scaling Head/Neck, Week 12 (n=28,53,42,84)0.6 ± 0.11.1 ± 0.10.5 ± 0.11.1 ± 0.1
Scaling Head/Neck, Week 16 (n=28,45,38,70)0.6 ± 0.20.8 ± 0.10.5 ± 0.10.9 ± 0.1
Erythema Upper limbs, Baseline (n=31,82,45,133)0.6 ± 0.10.6 ± 0.10.8 ± 0.10.5 ± 0.1
Erythema Upper limbs, Week 4 (n=30,82,43,128)0.8 ± 0.11.3 ± 0.10.8 ± 0.11.3 ± 0.1
Erythema Upper limbs, Week 8 (n=30,70,43,104)0.9 ± 0.21.5 ± 0.10.9 ± 0.11.4 ± 0.1
Erythema Upper limbs, Week 12 (n=28,53,42,84)1.0 ± 0.21.5 ± 0.10.9 ± 0.11.3 ± 0.1
Erythema Upper limbs, Week 16 (n=28,45,38,70)1.0 ± 0.21.4 ± 0.11.1 ± 0.11.3 ± 0.1
Induration Upper limbs, Baseline (n=31,82,45,133)0.7 ± 0.10.6 ± 0.10.6 ± 0.10.5 ± 0.1
Induration Upper limbs, Week 4 (n=30,82,43,128)0.8 ± 0.11.3 ± 0.10.7 ± 0.11.1 ± 0.1
Induration Upper limbs, Week 8 (n=30,70,43,104)0.8 ± 0.21.5 ± 0.10.8 ± 0.11.4 ± 0.1
Induration Upper limbs, Week 12 (n=28,53,42,84)1.0 ± 0.21.5 ± 0.11.0 ± 0.11.3 ± 0.1
Induration Upper limbs, Week 16 (n=28,45,38,70)1.1 ± 0.21.3 ± 0.21.1 ± 0.11.4 ± 0.1
Scaling Upper limbs, Baseline (n=31,82,45,133)0.8 ± 0.20.6 ± 0.10.7 ± 0.10.5 ± 0.1
Scaling Upper limbs, Week 4 (n=30,82,43,128)0.8 ± 0.21.3 ± 0.10.7 ± 0.11.2 ± 0.1
Scaling Upper limbs, Week 8 (n=30,70,43,104)0.9 ± 0.21.4 ± 0.10.8 ± 0.11.4 ± 0.1
Scaling Upper limbs, Week 12 (n=28,53,42,84)1.0 ± 0.21.4 ± 0.11.0 ± 0.11.4 ± 0.1
Scaling Upper limbs, Week 16 (n=28,45,38,70)1.1 ± 0.21.3 ± 0.21.3 ± 0.21.4 ± 0.1
Erythema Trunk, Baseline (n=31,82,45,133)0.5 ± 0.10.4 ± 0.10.4 ± 0.10.4 ± 0.1
Erythema Trunk, Week 4 (n=30,82,43,128)0.7 ± 0.21.1 ± 0.10.4 ± 0.11.1 ± 0.1
Erythema Trunk, Week 8 (n=30,70,43,104)0.9 ± 0.21.5 ± 0.10.5 ± 0.11.4 ± 0.1
Erythema Trunk, Week 12 (n=28,53,42,84)0.7 ± 0.21.5 ± 0.20.5 ± 0.11.1 ± 0.1
Erythema Trunk, Week 16 (n=28,45,38,70)0.9 ± 0.21.3 ± 0.20.5 ± 0.11.1 ± 0.1
Induration Trunk, Baseline (n=31,82,45,133)0.4 ± 0.10.3 ± 0.10.3 ± 0.10.3 ± 0.0
Induration Trunk, Week 4 (n=30,82,43,128)0.4 ± 0.10.9 ± 0.10.3 ± 0.10.8 ± 0.1
Induration Trunk, Week 8 (n=30,70,43,104)0.5 ± 0.11.2 ± 0.10.4 ± 0.11.1 ± 0.1
Induration Trunk, Week 12 (n=28,53,42,84)0.5 ± 0.21.2 ± 0.10.5 ± 0.10.9 ± 0.1
Induration Trunk, Week 16 (n=28,45,38,70)0.6 ± 0.21.2 ± 0.20.6 ± 0.11.1 ± 0.1
Scaling Trunk, Baseline (n=31,82,45,133)0.3 ± 0.10.3 ± 0.10.3 ± 0.10.3 ± 0.0
Scaling Trunk, Week 4 (n=30,82,43,128)0.4 ± 0.10.9 ± 0.10.3 ± 0.10.8 ± 0.1
Scaling Trunk, Week 8 (n=30,70,43,104)0.5 ± 0.11.2 ± 0.10.4 ± 0.11.1 ± 0.1
Scaling Trunk, Week 12 (n=28,53,42,84)0.4 ± 0.11.2 ± 0.10.5 ± 0.10.9 ± 0.1
Scaling Trunk, Week 16 (n=28,45,38,70)0.6 ± 0.21.1 ± 0.20.6 ± 0.11.0 ± 0.1
Erythema Lower limbs, Baseline (n=31,82,45,133)0.5 ± 0.10.6 ± 0.10.8 ± 0.10.5 ± 0.1
Erythema Lower limbs, Week 4 (n=30,82,43,128)0.6 ± 0.11.3 ± 0.10.8 ± 0.11.3 ± 0.1
Erythema Lower limbs, Week 8 (n=30,70,43,104)0.8 ± 0.21.6 ± 0.10.8 ± 0.21.5 ± 0.1
Erythema Lower limbs, Week 12 (n=28,53,42,84)0.8 ± 0.21.6 ± 0.20.9 ± 0.21.4 ± 0.1
Erythema Lower limbs, Week 16 (n=28,45,38,70)0.8 ± 0.21.6 ± 0.21.0 ± 0.21.3 ± 0.1
Induration Lower limbs, Baseline (n=31,82,45,133)0.5 ± 0.10.5 ± 0.10.6 ± 0.10.3 ± 0.0
Induration Lower limbs, Week 4 (n=30,82,43,128)0.6 ± 0.11.0 ± 0.10.6 ± 0.11.0 ± 0.1
Induration Lower limbs, Week 8 (n=30,70,43,104)0.6 ± 0.21.4 ± 0.10.6 ± 0.11.3 ± 0.1
Induration Lower limbs, Week 12 (n=28,53,42,84)0.6 ± 0.21.4 ± 0.10.8 ± 0.11.2 ± 0.1
Induration Lower limbs, Week 16 (n=28,45,38,70)0.6 ± 0.11.4 ± 0.20.9 ± 0.21.2 ± 0.1
Scaling Lower limbs, Baseline (n=31,82,45,133)0.5 ± 0.10.4 ± 0.10.6 ± 0.10.4 ± 0.0
Scaling Lower limbs, Week 4 (n=30,82,43,128)0.5 ± 0.11.0 ± 0.10.6 ± 0.11.0 ± 0.1
Scaling Lower limbs, Week 8 (n=30,70,43,104)0.7 ± 0.21.3 ± 0.10.6 ± 0.11.3 ± 0.1
Scaling Lower limbs, Week 12 (n=28,53,42,84)0.6 ± 0.21.4 ± 0.10.7 ± 0.11.3 ± 0.1
Scaling Lower limbs, Week 16 (n=28,45,38,70)0.6 ± 0.21.4 ± 0.20.9 ± 0.21.3 ± 0.1
SecondaryMean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Erythema Head/Neck, Baseline (n=27,75,42,120)0.7 ± 0.21.5 ± 0.10.5 ± 0.11.6 ± 0.1
Erythema Head/Neck, Week 4 (n=27,74,42,119)0.6 ± 0.11.1 ± 0.10.6 ± 0.10.7 ± 0.1
Erythema Head/Neck, Week 8 (n=26,72,41,118)0.8 ± 0.20.8 ± 0.10.5 ± 0.10.7 ± 0.1
Erythema Head/Neck, Week 16 (n=23,67,39,101)0.7 ± 0.21.0 ± 0.10.4 ± 0.10.6 ± 0.1
Induration Head/Neck, Baseline (n=27,75,42,120)0.5 ± 0.11.3 ± 0.10.4 ± 0.11.4 ± 0.1
Induration Head/Neck, Week 4 (n=27,74,42,119)0.3 ± 0.10.9 ± 0.10.4 ± 0.10.6 ± 0.1
Induration Head/Neck, Week 8 (n=26,72,41,118)0.4 ± 0.20.8 ± 0.10.3 ± 0.10.5 ± 0.1
Induration Head/Neck, Week 16 (n=23,67,39,101)0.4 ± 0.10.7 ± 0.10.2 ± 0.10.5 ± 0.1
Scaling Head/Neck, Baseline (n=27,75,42,120)0.6 ± 0.21.4 ± 0.10.5 ± 0.11.6 ± 0.1
Scaling Head/Neck, Week 4 (n=27,74,42,119)0.5 ± 0.21.0 ± 0.10.6 ± 0.10.7 ± 0.1
Scaling Head/Neck, Week 8 (n=26,72,41,118)0.7 ± 0.20.9 ± 0.10.5 ± 0.10.6 ± 0.1
Scaling Head/Neck, Week 16 (n=23,67,39,101)0.5 ± 0.20.9 ± 0.10.4 ± 0.10.5 ± 0.1
Erythema Upper limbs, Baseline (n=27,75,42,120)1.0 ± 0.21.9 ± 0.11.2 ± 0.21.8 ± 0.1
Erythema Upper limbs, Week 4 (n=27,74,42,119)0.9 ± 0.21.5 ± 0.11.1 ± 0.21.1 ± 0.1
Erythema Upper limbs, Week 8 (n=26,72,41,118)0.8 ± 0.21.2 ± 0.11.0 ± 0.11.0 ± 0.1
Erythema Upper limbs, Week 16 (n=23,67,39,101)1.0 ± 0.21.3 ± 0.11.1 ± 0.20.9 ± 0.1
Induration Upper limbs, Baseline (n=27,75,42,120)1.1 ± 0.21.9 ± 0.11.1 ± 0.11.7 ± 0.1
Induration Upper limbs, Week 4 (n=27,74,42,119)1.0 ± 0.21.4 ± 0.11.1 ± 0.11.1 ± 0.1
Induration Upper limbs, Week 8 (n=26,72,41,118)1.0 ± 0.21.2 ± 0.11.0 ± 0.11.0 ± 0.1
Induration Upper limbs, Week 16 (n=23,67,39,101)1.1 ± 0.21.2 ± 0.11.1 ± 0.20.9 ± 0.1
Scaling Upper limbs, Baseline (n=27,75,42,120)1.1 ± 0.21.8 ± 0.11.3 ± 0.21.8 ± 0.1
Scaling Upper limbs, Week 4 (n=27,74,42,119)1.1 ± 0.21.5 ± 0.11.1 ± 0.11.1 ± 0.1
Scaling Upper limbs, Week 8 (n=26,72,41,118)0.9 ± 0.21.2 ± 0.11.1 ± 0.11.0 ± 0.1
Scaling Upper limbs, Week 16 (n=23,67,39,101)1.2 ± 0.21.3 ± 0.11.1 ± 0.20.9 ± 0.1
Erythema Trunk, Baseline (n=27,75,42,120)0.9 ± 0.21.9 ± 0.10.7 ± 0.21.8 ± 0.1
Erythema Trunk, Week 4 (n=27,74,42,119)0.8 ± 0.21.4 ± 0.10.6 ± 0.11.0 ± 0.1
Erythema Trunk, Week 8 (n=26,72,41,118)0.8 ± 0.21.2 ± 0.10.7 ± 0.10.8 ± 0.1
Erythema Trunk, Week 16 (n=23,67,39,101)0.7 ± 0.21.1 ± 0.10.6 ± 0.20.8 ± 0.1
Induration Trunk, Baseline (n=27,75,42,120)0.7 ± 0.21.7 ± 0.10.7 ± 0.21.5 ± 0.1
Induration Trunk, Week 4 (n=27,74,42,119)0.6 ± 0.21.2 ± 0.10.6 ± 0.10.8 ± 0.1
Induration Trunk, Week 8 (n=26,72,41,118)0.5 ± 0.21.0 ± 0.10.6 ± 0.10.7 ± 0.1
Induration Trunk, Week 16 (n=23,67,39,101)0.5 ± 0.20.9 ± 0.10.6 ± 0.10.7 ± 0.1
Scaling Trunk, Baseline (n=27,75,42,120)0.7 ± 0.21.6 ± 0.10.7 ± 0.21.5 ± 0.1
Scaling Trunk, Week 4 (n=27,74,42,119)0.5 ± 0.11.3 ± 0.10.6 ± 0.10.9 ± 0.1
Scaling Trunk, Week 8 (n=26,72,41,118)0.5 ± 0.11.0 ± 0.10.6 ± 0.10.7 ± 0.1
Scaling Trunk, Week 16 (n=23,67,39,101)0.4 ± 0.10.9 ± 0.10.6 ± 0.10.7 ± 0.1
Erythema Lower limbs, Baseline (n=27,75,42,120)0.7 ± 0.22.1 ± 0.11.1 ± 0.21.9 ± 0.1
Erythema Lower limbs, Week 4 (n=27,74,42,119)0.7 ± 0.21.6 ± 0.11.0 ± 0.21.3 ± 0.1
Erythema Lower limbs, Week 8 (n=26,72,41,118)0.8 ± 0.21.3 ± 0.10.9 ± 0.21.0 ± 0.1
Erythema Lower limbs, Week 16 (n=23,67,39,101)1.0 ± 0.21.3 ± 0.10.9 ± 0.20.9 ± 0.1
Induration Lower limbs, Baseline (n=27,75,42,120)0.6 ± 0.11.9 ± 0.11.0 ± 0.21.7 ± 0.1
Induration Lower limbs, Week 4 (n=27,74,42,119)0.7 ± 0.21.5 ± 0.10.9 ± 0.21.0 ± 0.1
Induration Lower limbs, Week 8 (n=26,72,41,118)0.7 ± 0.21.3 ± 0.10.9 ± 0.20.9 ± 0.1
Induration Lower limbs, Week 16 (n=23,67,39,101)0.9 ± 0.21.1 ± 0.10.9 ± 0.20.8 ± 0.1
Scaling Lower limbs, Baseline (n=27,75,42,120)0.6 ± 0.21.8 ± 0.11.0 ± 0.21.8 ± 0.1
Scaling Lower limbs, Week 4 (n=27,74,42,119)0.7 ± 0.21.5 ± 0.10.9 ± 0.21.1 ± 0.1
Scaling Lower limbs, Week 8 (n=26,72,41,118)0.7 ± 0.21.2 ± 0.10.8 ± 0.21.0 ± 0.1
Scaling Lower limbs, Week 16 (n=23,67,39,101)1.0 ± 0.21.1 ± 0.10.8 ± 0.20.8 ± 0.1
SecondaryMean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Erythema Head/Neck, Week 4 (n=326,331)-0.8 ± 0.1-1.2 ± 0.1
Erythema Head/Neck, Week 8 (n=322,323)-1.1 ± 0.1-1.5 ± 0.1
Erythema Head/Neck, Week 16 (n=311,307)-1.2 ± 0.1-1.6 ± 0.1
Erythema Head/Neck, Week 24 (n=277,279)-1.2 ± 0.1-1.6 ± 0.1
Induration Head/Neck, Week 4 (n=326,331)-0.8 ± 0.0-1.1 ± 0.1
Induration Head/Neck, Week 8 (n=322,323)-1.1 ± 0.1-1.4 ± 0.1
Induration Head/Neck, Week 16 (n=311,307)-1.2 ± 0.1-1.4 ± 0.1
Induration Head/Neck, Week 24 (n=277,279)-1.1 ± 0.1-1.4 ± 0.1
Scaling Head/Neck, Week 4 (n=326,331)-0.9 ± 0.1-1.1 ± 0.1
Scaling Head/Neck, Week 8 (n=322,323)-1.2 ± 0.1-1.5 ± 0.1
Scaling Head/Neck, Week 16 (n=311,307)-1.3 ± 0.1-1.5 ± 0.1
Scaling Head/Neck, Week 24 (n=277,279)-1.2 ± 0.1-1.5 ± 0.1
Erythema Upper limbs, Week 4 (n=326,331)-0.9 ± 0.0-1.2 ± 0.0
Erythema Upper limbs, Week 8 (n=322,323)-1.3 ± 0.1-1.5 ± 0.1
Erythema Upper limbs, Week 16 (n=311,307)-1.4 ± 0.1-1.7 ± 0.1
Erythema Upper limbs, Week 24 (n=277,279)-1.5 ± 0.1-1.8 ± 0.1
Induration Upper limbs, Week 4 (n=326,331)-0.8 ± 0.0-1.2 ± 0.1
Induration Upper limbs, Week 8 (n=322,323)-1.1 ± 0.1-1.5 ± 0.1
Induration Upper limbs, Week 16 (n=311,307-1.2 ± 0.1-1.6 ± 0.1
Induration Upper limbs, Week 24 (n=277,279)-1.2 ± 0.1-1.6 ± 0.1
Scaling Upper limbs, Week 4 (n=326,331)-0.7 ± 0.0-1.1 ± 0.1
Scaling Upper limbs, Week 8 (n=322,323)-1.1 ± 0.1-1.5 ± 0.1
Scaling Upper limbs, Week 16 (n=311,307)-1.2 ± 0.1-1.6 ± 0.1
Scaling Upper limbs, Week 24 (n=277,279)-1.3 ± 0.1-1.6 ± 0.1
Erythema Trunk, Week 4 (n=326,331)-0.9 ± 0.0-1.3 ± 0.1
Erythema Trunk, Week 8 (n=322,323)-1.3 ± 0.1-1.7 ± 0.1
Erythema Trunk, Week 16 (n=311,307)-1.5 ± 0.1-1.9 ± 0.1
Erythema Trunk, Week 24 (n=277,279)-1.5 ± 0.1-2.0 ± 0.1
Induration Trunk, Week 4 (n=326,331)-0.8 ± 0.0-1.2 ± 0.1
Induration Trunk, Week 8 (n=322,323)-1.2 ± 0.1-1.7 ± 0.1
Induration Trunk, Week 16 (n=311,307)-1.4 ± 0.1-1.8 ± 0.1
Induration Trunk, Week 24 (n=277,279)-1.4 ± 0.1-1.9 ± 0.1
Scaling Trunk, Week 4 (n=326,331)-0.8 ± 0.1-1.1 ± 0.1
Scaling Trunk, Week 8 (n=322,323)-1.2 ± 0.1-1.6 ± 0.1
Scaling Trunk, Week 16 (n=311,307)-1.4 ± 0.1-1.8 ± 0.1
Scaling Trunk, Week 24 (n=277,279)-1.4 ± 0.1-1.8 ± 0.1
Erythema Lower limbs, Week 4 (n=326,331)-0.9 ± 0.0-1.2 ± 0.0
Erythema Lower limbs, Week 8 (n=322,323)-1.3 ± 0.1-1.7 ± 0.1
Erythema Lower limbs, Week 16 (n=311,307)-1.6 ± 0.1-2.0 ± 0.1
Erythema Lower limbs, Week 24 (n=277,279)-1.7 ± 0.1-2.1 ± 0.1
Induration Lower limbs, Week 4 (n=326,331)-0.8 ± 0.0-1.3 ± 0.1
Induration Lower limbs, Week 8 (n=322,323)-1.2 ± 0.1-1.7 ± 0.1
Induration Lower limbs, Week 16 (n=311,307)-1.5 ± 0.1-2.0 ± 0.1
Induration Lower limbs, Week 24 (n=277,279)-1.6 ± 0.1-2.0 ± 0.1
Scaling Lower limbs, Week 4 (n=326,331)-0.9 ± 0.0-1.2 ± 0.1
Scaling Lower limbs, Week 8 (n=322,323)-1.3 ± 0.1-1.8 ± 0.1
Scaling Lower limbs, Week 16 (n=311,307)-1.6 ± 0.1-2.0 ± 0.1
Scaling Lower limbs, Week 24 (n=277,279)-1.6 ± 0.1-2.0 ± 0.1
SecondaryMean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for CP-690,550 5 mg BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 (Period B)
Erythema Head/Neck, Week 4 (n=30,82,43,128)0.1 ± 0.10.8 ± 0.10.2 ± 0.10.8 ± 0.1
Erythema Head/Neck, Week 8 (n=30,70,43,104)0.2 ± 0.20.9 ± 0.10.1 ± 0.11.1 ± 0.1
Erythema Head/Neck, Week 12 (n=28,53,42,84)0.2 ± 0.10.8 ± 0.10.2 ± 0.10.9 ± 0.1
Erythema Head/Neck, Week 16 (n=28,45,38,70)0.1 ± 0.10.6 ± 0.10.2 ± 0.10.8 ± 0.1
Induration Head/Neck, Week 4 (n=30,82,43,128)0.1 ± 0.10.5 ± 0.10.1 ± 0.10.7 ± 0.1
Induration Head/Neck, Week 8 (n=30,70,43,104)0.1 ± 0.10.7 ± 0.10.2 ± 0.10.9 ± 0.1
Induration Head/Neck, Week 12 (n=28,53,42,84)0.1 ± 0.10.6 ± 0.10.3 ± 0.10.8 ± 0.1
Induration Head/Neck, Week 16 (n=28,45,38,70)0.1 ± 0.10.5 ± 0.10.2 ± 0.10.7 ± 0.1
Scaling Head/Neck, Week 4 (n=30,82,43,128)0.0 ± 0.10.6 ± 0.10.2 ± 0.10.8 ± 0.1
Scaling Head/Neck, Week 8 (n=30,70,43,104)0.1 ± 0.10.8 ± 0.10.2 ± 0.11.0 ± 0.1
Scaling Head/Neck, Week 12 (n=28,53,42,84)0.1 ± 0.10.7 ± 0.10.3 ± 0.11.0 ± 0.1
Scaling Head/Neck, Week 16 (n=28,45,38,70)0.1 ± 0.10.7 ± 0.10.3 ± 0.10.8 ± 0.1
Erythema Upper limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.7 ± 0.10.1 ± 0.10.7 ± 0.1
Erythema Upper limbs, Week 8 (n=30,70,43,104)0.3 ± 0.10.9 ± 0.10.2 ± 0.10.9 ± 0.1
Erythema Upper limbs, Week 12 (n=28,53,42,84)0.4 ± 0.20.9 ± 0.10.2 ± 0.10.9 ± 0.1
Erythema Upper limbs, Week 16 (n=28,45,38,70)0.4 ± 0.10.8 ± 0.10.4 ± 0.10.9 ± 0.1
Induration Upper limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.6 ± 0.10.1 ± 0.10.6 ± 0.1
Induration Upper limbs, Week 8 (n=30,70,43,104)0.2 ± 0.10.9 ± 0.10.2 ± 0.10.9 ± 0.1
Induration Upper limbs, Week 12 (n=28,53,42,84)0.4 ± 0.20.9 ± 0.10.4 ± 0.10.9 ± 0.1
Induration Upper limbs, Week 16 (n=28,45,38,70)0.4 ± 0.20.9 ± 0.10.5 ± 0.10.9 ± 0.1
Scaling Upper limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.7 ± 0.10.1 ± 0.10.7 ± 0.1
Scaling Upper limbs, Week 8 (n=30,70,43,104)0.1 ± 0.10.9 ± 0.10.1 ± 0.10.9 ± 0.1
Scaling Upper limbs, Week 12 (n=28,53,42,84)0.3 ± 0.10.9 ± 0.10.3 ± 0.11.0 ± 0.1
Scaling Upper limbs, Week 16 (n=28,45,38,70)0.3 ± 0.20.9 ± 0.10.6 ± 0.11.1 ± 0.1
Erythema Trunk, Week 4 (n=30,82,43,128)0.2 ± 0.10.7 ± 0.10.0 ± 0.10.7 ± 0.1
Erythema Trunk, Week 8 (n=30,70,43,104)0.4 ± 0.11.0 ± 0.10.1 ± 0.11.0 ± 0.1
Erythema Trunk, Week 12 (n=28,53,42,84)0.1 ± 0.11.2 ± 0.20.2 ± 0.10.8 ± 0.1
Erythema Trunk, Week 16 (n=28,45,38,70)0.3 ± 0.21.0 ± 0.20.2 ± 0.10.8 ± 0.1
Induration Trunk, Week 4 (n=30,82,43,128)-0.0 ± 0.10.6 ± 0.10.0 ± 0.10.5 ± 0.1
Induration Trunk, Week 8 (n=30,70,43,104)0.1 ± 0.10.9 ± 0.10.2 ± 0.10.8 ± 0.1
Induration Trunk, Week 12 (n=28,53,42,84)0.1 ± 0.11.0 ± 0.10.3 ± 0.10.7 ± 0.1
Induration Trunk, Week 16 (n=28,45,38,70)0.2 ± 0.11.0 ± 0.20.3 ± 0.10.8 ± 0.1
Scaling Trunk, Week 4 (n=30,82,43,128)0.1 ± 0.10.6 ± 0.1-0.0 ± 0.10.5 ± 0.1
Scaling Trunk, Week 8 (n=30,70,43,104)0.2 ± 0.10.9 ± 0.10.2 ± 0.10.9 ± 0.1
Scaling Trunk, Week 12 (n=28,53,42,84)0.1 ± 0.10.9 ± 0.10.2 ± 0.10.6 ± 0.1
Scaling Trunk, Week 16 (n=28,45,38,70)0.4 ± 0.20.9 ± 0.20.3 ± 0.20.8 ± 0.1
Erythema Lower limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.7 ± 0.10.0 ± 0.10.8 ± 0.1
Erythema Lower limbs, Week 8 (n=30,70,43,104)0.3 ± 0.21.0 ± 0.1-0.0 ± 0.11.1 ± 0.1
Erythema Lower limbs, Week 12 (n=28,53,42,84)0.3 ± 0.21.0 ± 0.10.1 ± 0.21.0 ± 0.1
Erythema Lower limbs, Week 16 (n=28,45,38,70)0.3 ± 0.21.1 ± 0.20.3 ± 0.20.9 ± 0.1
Induration Lower limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.5 ± 0.10.0 ± 0.10.7 ± 0.1
Induration Lower limbs, Week 8 (n=30,70,43,104)0.1 ± 0.20.9 ± 0.10.0 ± 0.11.0 ± 0.1
Induration Lower limbs, Week 12 (n=28,53,42,84)0.1 ± 0.20.9 ± 0.10.2 ± 0.10.9 ± 0.1
Induration Lower limbs, Week 16 (n=28,45,38,70)0.1 ± 0.10.9 ± 0.10.4 ± 0.20.9 ± 0.1
Scaling Lower limbs, Week 4 (n=30,82,43,128)0.1 ± 0.10.6 ± 0.1-0.0 ± 0.10.6 ± 0.1
Scaling Lower limbs, Week 8 (n=30,70,43,104)0.3 ± 0.20.9 ± 0.1-0.0 ± 0.10.9 ± 0.1
Scaling Lower limbs, Week 12 (n=28,53,42,84)0.2 ± 0.20.9 ± 0.10.0 ± 0.10.9 ± 0.1
Scaling Lower limbs, Week 16 (n=28,45,38,70)0.2 ± 0.21.0 ± 0.10.3 ± 0.21.0 ± 0.1
SecondaryMean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)

Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Erythema Head/Neck, Week 4 (n=27,74,42,119)-0.1 ± 0.1-0.4 ± 0.10.1 ± 0.1-0.9 ± 0.1
Erythema Head/Neck, Week 8 (n=26,72,41,118)0.1 ± 0.1-0.7 ± 0.1-0.0 ± 0.1-0.9 ± 0.1
Erythema Head/Neck, Week 16 (n=23,67,39,101)-0.1 ± 0.1-0.4 ± 0.1-0.1 ± 0.1-0.9 ± 0.1
Induration Head/Neck, Week 4 (n=27,74,42,119)-0.2 ± 0.1-0.4 ± 0.10.0 ± 0.1-0.8 ± 0.1
Induration Head/Neck, Week 8 (n=26,72,41,118)-0.0 ± 0.2-0.5 ± 0.1-0.0 ± 0.1-0.8 ± 0.1
Induration Head/Neck, Week 16 (n=23,67,39,101)-0.1 ± 0.1-0.6 ± 0.1-0.2 ± 0.1-0.9 ± 0.1
Scaling Head/Neck, Week 4 (n=27,74,42,119)-0.1 ± 0.1-0.4 ± 0.10.0 ± 0.1-0.9 ± 0.1
Scaling Head/Neck, Week 8 (n=26,72,41,118)0.1 ± 0.1-0.5 ± 0.1-0.0 ± 0.1-0.9 ± 0.1
Scaling Head/Neck, Week 16 (n=23,67,39,101)-0.1 ± 0.1-0.5 ± 0.1-0.2 ± 0.1-1.0 ± 0.1
Erythema Upper limbs, Week 4 (n=27,74,42,119)-0.0 ± 0.1-0.4 ± 0.1-0.0 ± 0.1-0.6 ± 0.1
Erythema Upper limbs, Week 8 (n=26,72,41,118)-0.1 ± 0.1-0.7 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Erythema Upper limbs, Week 16 (n=23,67,39,101)0.0 ± 0.2-0.6 ± 0.1-0.2 ± 0.2-0.8 ± 0.1
Induration Upper limbs, Week 4 (n=27,74,42,119)-0.0 ± 0.1-0.5 ± 0.1-0.0 ± 0.1-0.6 ± 0.1
Induration Upper limbs, Week 8 (n=26,72,41,118)-0.0 ± 0.1-0.7 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Induration Upper limbs, Week 16 (n=23,67,39,101)-0.0 ± 0.2-0.6 ± 0.1-0.1 ± 0.2-0.8 ± 0.1
Scaling Upper limbs, Week 4 (n=27,74,42,119)0.0 ± 0.1-0.3 ± 0.1-0.2 ± 0.1-0.7 ± 0.1
Scaling Upper limbs, Week 8 (n=26,72,41,118)-0.0 ± 0.2-0.6 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Scaling Upper limbs, Week 16 (n=23,67,39,101)0.0 ± 0.2-0.5 ± 0.1-0.2 ± 0.2-0.8 ± 0.1
Erythema Trunk, Week 4 (n=27,74,42,119)-0.1 ± 0.1-0.5 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Erythema Trunk, Week 8 (n=26,72,41,118)-0.1 ± 02-0.7 ± 010.0 ± 0.2-1.0 ± 0.1
Erythema Trunk, Week 16 (n=23,67,39,101)-0.2 ± 0.2-0.8 ± 0.1-0.1 ± 0.2-1.0 ± 0.1
Induration Trunk, Week 4 (n=27,74,42,119)-0.1 ± 0.1-0.5 ± 0.1-0.1 ± 0.1-0.7 ± 0.1
Induration Trunk, Week 8 (n=26,72,41,118)-0.1 ± 0.1-0.7 ± 0.1-0.2 ± 0.1-0.8 ± 0.1
Induration Trunk, Week 16 (n=23,67,39,101)-0.2 ± 0.2-0.8 ± 0.1-0.2 ± 0.2-0.8 ± 0.1
Scaling Trunk, Week 4 (n=27,74,42,119)-0.2 ± 0.2-0.4 ± 0.1-0.1 ± 0.1-0.6 ± 0.1
Scaling Trunk, Week 8 (n=26,72,41,118)0.0 ± 0.1-0.6 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Scaling Trunk, Week 16 (n=23,67,39,101)-0.3 ± 0.2-0.7 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Erythema Lower limbs, Week 4 (n=27,74,42,119)0.0 ± 0.1-0.5 ± 0.1-0.1 ± 0.1-0.7 ± 0.1
Erythema Lower limbs, Week 8 (n=26,72,41,118)0.1 ± 0.1-0.7 ± 0.1-0.2 ± 0.1-0.9 ± 0.1
Erythema Lower limbs, Week 16 (n=23,67,39,101)0.2 ± 0.2-0.7 ± 0.1-0.2 ± 0.2-1.0 ± 0.1
Induration Lower limbs, Week 4 (n=27,74,42,119)0.2 ± 0.1-0.4 ± 0.1-0.1 ± 0.1-0.7 ± 0.1
Induration Lower limbs, Week 8 (n=26,72,41,118)0.1 ± 0.2-0.6 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Induration Lower limbs, Week 16 (n=23,67,39,101)0.3 ± 0.2-0.7 ± 0.1-0.1 ± 0.2-0.9 ± 0.1
Scaling Lower limbs, Week 4 (n=27,74,42,119)0.1 ± 0.1-0.3 ± 0.1-0.1 ± 0.1-0.7 ± 0.1
Scaling Lower limbs, Week 8 (n=26,72,41,118)0.1 ± 0.2-0.6 ± 0.1-0.1 ± 0.1-0.8 ± 0.1
Scaling Lower limbs, Week 16 (n=23,67,39,101)0.3 ± 0.2-0.6 ± 0.1-0.2 ± 0.2-0.9 ± 0.1
SecondaryPercentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A

PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 428.70 (23.83 to 33.57)54.63 (49.30 to 59.96)
Week 855.29 (49.93 to 60.64)75.52 (70.92 to 80.13)
Week 1665.26 (60.13 to 70.39)79.40 (75.07 to 83.73)
Week 2459.52 (54.23 to 64.80)73.13 (68.39 to 77.88)
SecondaryPercentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A

PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 41.21 (0.03 to 2.39)6.27 (3.67 to 8.86)
Week 88.76 (5.72 to 11.81)24.78 (20.15 to 29.40)
Week 1618.73 (14.53 to 22.93)36.72 (31.55 to 41.88)
Week 2420.24 (15.91 to 24.57)37.31 (32.13 to 42.49)
SecondaryPercentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A

PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 40.91 (0.0 to 1.93)2.09 (0.56 to 3.62)
Week 82.72 (0.97 to 4.47)7.46 (4.65 to 10.28)
Week 167.25 (4.46 to 10.04)15.82 (11.91 to 19.73)
Week 248.16 (5.21 to 11.11)17.31 (13.26 to 21.37)
SecondaryPercentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline96.30 (89.17 to 100.00)42.67 (31.47 to 53.86)92.86 (85.07 to 100.00)49.17 (40.22 to 58.11)
Week 4100.00 (100.00 to 100.00)69.33 (58.90 to 79.77)92.86 (85.07 to 100.00)84.17 (77.64 to 90.70)
Week 892.59 (82.71 to 100.00)81.33 (72.52 to 90.15)95.24 (88.80 to 100.00)89.17 (83.61 to 94.73)
Week 1685.19 (71.79 to 98.58)82.67 (74.10 to 91.23)85.71 (75.13 to 96.30)79.17 (71.90 to 86.43)
SecondaryPercentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline48.15 (29.30 to 66.99)12.00 (4.65 to 19.35)45.24 (30.19 to 60.29)15.83 (9.30 to 22.36)
Week 448.15 (29.30 to 66.99)17.33 (8.77 to 25.90)47.62 (32.51 to 62.72)35.00 (26.47 to 43.53)
Week 848.15 (29.3 to 66.99)21.33 (12.06 to 30.60)47.62 (32.51 to 62.72)42.50 (33.66 to 51.34)
Week 1633.33 (15.55 to 51.11)21.33 (12.06 to 30.60)45.24 (30.19 to 60.29)44.17 (35.28 to 53.05)
SecondaryPercentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline18.52 (3.87 to 33.17)5.33 (0.25 to 10.42)23.81 (10.93 to 36.69)5.00 (1.10 to 8.90)
Week 418.52 (3.87 to 33.17)9.33 (2.75 to 15.92)21.43 (9.02 to 33.84)15.00 (8.61 to 21.39)
Week 818.52 (3.87 to 33.17)13.33 (5.64 to 21.03)21.43 (9.02 to 33.84)19.17 (12.12 to 26.21)
Week 1614.81 (1.42 to 28.21)10.67 (3.68 to 17.65)26.19 (12.89 to 39.49)20.83 (13.57 to 28.10)
SecondaryPercentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)

PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 4 (n=326,331)0.92 (0.00 to 1.96)0.60 (0.00 to 1.44)
Week 8 (n=322,323)0.62 (0.00 to 1.48)0.62 (0.00 to 1.47)
Week 16 (n=311,307)0.96 (0.00 to 2.05)0.98 (0.00 to 2.08)
Week 24 (n=277,279)1.08 (0.00 to 2.30)0.36 (0.00 to 1.06)
Overall (n=329,333)2.13 (0.57 to 3.69)2.10 (0.56 to 3.64)
SecondaryPercentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,128)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 8 (n=30,70,43,104)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 12 (n=28,53,42,84)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (-3.51 to 1.13)1.19
Week 16 (n=28,45,38,70)0.000.000.000.00
Overall (n=31,82,45,132)0.000.000.000.76
SecondaryPercentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)

PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 4 (n=27,74,42,119)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 8 (n=26,72,41,118)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 16 (n=23,67,39,101)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)2.56 (0.00 to 7.52)0.00 (0.00 to 0.00)
Overall (n=27,75,42,120)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)2.38 (0.00 to 6.99)0.00 (0.00 to 0.00)
SecondaryMean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline (n=331,335)6.7 ± 0.16.9 ± 0.1
Week 4 (n=326,331)3.2 ± 0.12.2 ± 0.1
Week 8 (n=322,321)2.8 ± 0.11.6 ± 0.1
Week 16 (n=310,307)2.9 ± 0.21.7 ± 0.1
Week 24 (n=274,278)2.9 ± 0.21.6 ± 0.1
SecondaryMean ISI Score During the Double-Blind Treatment Withdrawal (Period B)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline (n=31,82,45,133)1.5 ± 0.41.2 ± 0.20.6 ± 0.20.8 ± 0.1
Week 4 (n=30,82,43,127)1.7 ± 0.43.6 ± 0.30.7 ± 0.24.1 ± 0.3
Week 8 (n=30,69,43,104)1.5 ± 0.44.0 ± 0.41.2 ± 0.34.1 ± 0.3
Week 12 (n=29,53,41,84)1.9 ± 0.44.0 ± 0.41.3 ± 0.33.8 ± 0.3
Week 16 (n=28,45,38,70)2.2 ± 0.53.7 ± 0.41.6 ± 0.44.0 ± 0.4
SecondaryMean ISI Score During the CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean ISI Score During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline (n=27,75,42,120)2.3 ± 0.54.9 ± 0.31.7 ± 0.45.2 ± 0.3
Week 4 (n=27,74,42,119)2.6 ± 0.52.6 ± 0.21.7 ± 0.42.1 ± 0.2
Week 8 (n=26,72,41,118)2.4 ± 0.52.3 ± 0.21.5 ± 0.31.8 ± 0.2
Week 16 (n=23,67,39,100)2.3 ± 0.52.2 ± 0.31.4 ± 0.41.6 ± 0.2
SecondaryMean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 4 (n=326,331)-3.6 ± 0.1-4.6 ± 0.2
Week 8 (n=322,321)-3.9 ± 0.2-5.3 ± 0.2
Week 16 (n=310,307)-3.8 ± 0.2-5.2 ± 0.2
Week 24 (n=274,278)-3.7 ± 0.2-5.3 ± 0.2
SecondaryMean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-B defined as the last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,127)0.2 ± 0.32.4 ± 0.30.1 ± 0.23.3 ± 0.3
Week 8 (n=30,69,43,104)-0.0 ± 0.32.9 ± 0.30.6 ± 0.23.4 ± 0.3
Week 12 (n=29,53,41,84)0.3 ± 0.22.8 ± 0.30.7 ± 0.23.2 ± 0.3
Week 16 (n=28,45,38,70)0.6 ± 0.32.7 ± 0.40.9 ± 0.33.6 ± 0.4
SecondaryMean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 4 (n=27,74,42,119)0.3 ± 0.4-2.3 ± 0.30.0 ± 0.2-3.1 ± 0.3
Week 8 (n=26,72,41,118)0.1 ± 0.4-2.6 ± 0.3-0.2 ± 0.2-3.4 ± 0.3
Week 16 (n=23,67,39,100)0.4 ± 0.4-2.6 ± 0.4-0.3 ± 0.3-3.6 ± 0.3
SecondaryPercentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 412.92 (9.28 to 16.57)25.69 (20.95 to 30.42)
Week 816.92 (12.85 to 21.00)41.28 (35.95 to 46.62)
Week 1620.00 (15.65 to 24.35)37.92 (32.66 to 43.18)
Week 2419.38 (15.09 to 23.68)37.31 (32.07 to 42.55)
SecondaryPercentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 40.00 (0.00 to 0.00)11.27 (3.91 to 18.62)7.41 (0.00 to 17.29)23.08 (14.98 to 31.17)
Week 85.56 (0.00 to 16.14)18.31 (9.31 to 27.31)18.52 (3.87 to 33.17)38.46 (29.11 to 47.81)
Week 1611.11 (0.00 to 25.63)15.49 (7.08 to 23.91)25.93 (9.40 to 42.46)28.85 (20.14 to 37.55)
SecondaryPercentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 427.62 (22.68 to 32.56)46.03 (40.53 to 51.54)
Week 834.29 (29.04 to 39.53)60.00 (54.59 to 65.41)
Week 1634.92 (29.66 to 40.19)60.00 (54.59 to 65.41)
Week 2431.11 (26.00 to 36.22)55.24 (49.75 to 60.73)
SecondaryPercentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 414.29 (0.00 to 32.62)22.58 (12.17 to 32.99)14.29 (0.00 to 32.62)41.05 (31.16 to 50.94)
Week 821.43 (0.00 to 42.92)33.87 (22.09 to 45.65)21.43 (0.00 to 42.92)55.79 (45.80 to 65.78)
Week 1621.43 (0.00 to 42.92)41.94 (29.65 to 54.22)35.71 (10.61 to 60.81)50.53 (40.47 to 60.58)
SecondaryPercentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 481.59 (77.31 to 85.87)88.89 (85.42 to 92.36)
Week 880.32 (75.93 to 84.71)87.94 (84.34 to 91.53)
Week 1673.97 (69.12 to 78.81)84.76 (80.79 to 88.73)
Week 2465.71 (60.47 to 70.96)74.92 (70.13 to 79.71)
SecondaryPercentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 428.57 (4.91 to 52.24)61.29 (49.17 to 73.41)14.29 (0.00 to 32.62)80.00 (71.96 to 88.04)
Week 828.57 (4.91 to 52.24)64.52 (52.61 to 76.43)28.57 (4.91 to 52.24)78.95 (70.75 to 87.15)
Week 1621.43 (0.00 to 42.92)62.90 (50.88 to 74.93)28.57 (4.91 to 52.24)69.47 (60.21 to 78.73)
SecondaryISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response
percentage of participantsCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Week 427.8 (23.2 to 33.2)47.2 (41.8 to 52.9)
Week 841.2 (36.0 to 46.9)67.8 (62.5 to 72.9)
Week 1652.4 (46.8 to 58.2)78.6 (73.7 to 83.1)
Week 2472.4 (55.1 to 87.3)83.4 (77.9 to 88.2)
SecondaryMedian Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Median · weeks
Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)
weeksCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)16.4 (16.1 to 24.6)8.0 (5.1 to 8.1)
SecondaryISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 414.3 (3.8 to 46.1)22.8 (14.2 to 35.5)14.3 (3.8 to 46.1)41.3 (32.1 to 51.9)
Week 828.6 (11.8 to 59.4)37.9 (27.0 to 51.4)21.4 (7.5 to 52.8)59.8 (50.0 to 69.7)
Week 1640.5 (18.3 to 73.5)79.1 (46.8 to 98.0)49.5 (21.8 to 85.0)90.3 (69.9 to 98.9)
SecondaryMedian Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)NA (NA to NA)16.1 (10.1 to NA)NA (NA to NA)8.3 (6.0 to 12.4)
SecondaryISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response
percentage of participantsCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Week 482.2 (77.8 to 86.2)90.3 (86.7 to 93.3)
Week 889.5 (85.8 to 92.6)96.5 (94.0 to 98.2)
Week 1693.6 (90.5 to 96.0)97.8 (95.5 to 99.1)
Week 2496.2 (92.5 to 98.4)97.8 (95.5 to 99.1)
SecondaryMedian Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Median · weeks
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)
weeksCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)4.1 (NA to NA)4.1 (NA to NA)
SecondaryISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 428.6 (11.8 to 59.4)61.8 (49.9 to 73.8)14.3 (3.8 to 46.1)80.0 (71.5 to 87.3)
Week 835.7 (16.7 to 65.7)75.1 (63.8 to 85.1)28.6 (11.8 to 59.4)86.7 (78.9 to 92.6)
Week 1657.1 (25.6 to 91.1)100.0 (NA to NA)36.5 (17.0 to 66.9)91.0 (83.6 to 95.9)
SecondaryMedian Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)

The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)16.6 (4.4 to NA)4.9 (4.3 to 7.1)NA (NA to NA)4.3 (4.1 to 4.4)
SecondaryMean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline (n=330,333)12.6 ± 0.412.6 ± 0.4
Week 4 (n=326,330)6.8 ± 0.34.8 ± 0.3
Week 8 (n=321,319)5.4 ± 0.33.4 ± 0.3
Week 16 (n=310,303)4.7 ± 0.32.9 ± 0.3
Week 24 (n=273,277)5.1 ± 0.42.6 ± 0.3
SecondaryMean DLQI Score During the CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline (n=27,75,42,120)3.6 ± 1.07.0 ± 0.82.2 ± 0.58.8 ± 0.7
Week 4 (n=27,74,42,119)3.4 ± 1.04.3 ± 0.52.2 ± 0.53.9 ± 0.4
Week 8 (n=26,71,41,118)3.9 ± 1.33.1 ± 0.42.2 ± 0.52.7 ± 0.4
Week 16 (n=22,66,39,101)3.0 ± 1.03.4 ± 0.52.1 ± 0.72.4 ± 0.4
SecondaryMean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline (n=31,82,45,133)2.6 ± 0.71.8 ± 0.31.2 ± 0.31.2 ± 0.2
Week 4 (n=30,82,43,127)3.4 ± 0.94.7 ± 0.51.3 ± 0.45.9 ± 0.6
Week 8 (n=30,68,43,104)3.1 ± 0.95.9 ± 0.81.6 ± 0.56.4 ± 0.7
Week 12 (n=28,52,41,83)3.3 ± 1.14.7 ± 0.61.9 ± 0.45.3 ± 0.7
Week 16 (n=28,44,38,68)3.5 ± 1.05.0 ± 0.72.0 ± 0.46.2 ± 0.8
SecondaryMean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 4 (n=325,328)-5.8 ± 0.3-7.6 ± 0.3
Week 8 (n=320,317)-7.1 ± 0.3-9.1 ± 0.4
Week 16 (n=309,301)-7.6 ± 0.4-9.4 ± 0.4
Week 24 (n=272,275)-7.1 ± 0.4-9.7 ± 0.4
SecondaryMean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)
scores on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 4 (n=30,82,43,127)0.8 ± 0.73.0 ± 0.50.1 ± 0.34.6 ± 0.5
Week 8 (n=30,68,43,104)0.5 ± 0.34.1 ± 0.70.3 ± 0.55.4 ± 0.6
Week 12 (n=28,52,41,83)0.9 ± 0.53.4 ± 0.50.6 ± 0.44.5 ± 0.7
Week 16 (n=28,44,38,68)1.1 ± 0.53.6 ± 0.60.5 ± 0.35.4 ± 0.8
SecondaryMean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 4 (n=27,74,42,119)-0.2 ± 0.2-2.9 ± 0.50.0 ± 0.4-4.9 ± 0.6
Week 8 (n=26,71,41,118)0.2 ± 0.4-3.4 ± 0.5-0.0 ± 0.5-5.9 ± 0.6
Week 16 (n=22,66,39,101)0.5 ± 0.8-3.3 ± 0.8-0.0 ± 0.7-6.3 ± 0.7
SecondaryMean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Daily Activities, Baseline (n=330,333)2.7 ± 0.102.7 ± 0.10
Daily Activities, Week 4 (n=326,330)1.5 ± 0.091.1 ± 0.07
Daily Activities, Week 8 (n=321,320)1.2 ± 0.080.8 ± 0.07
Daily Activities, Week 16 (n=310,303)1.0 ± 0.080.6 ± 0.07
Daily Activities, Week 24 (n=273,277)1.1 ± 0.090.6 ± 0.07
Personal Relationships, Baseline (n=331,332)1.7 ± 0.101.7 ± 0.10
Personal Relationships, Week 4 (n=326,330)1.0 ± 0.080.6 ± 0.07
Personal Relationships, Week 8 (n=321,318)0.7 ± 0.060.4 ± 0.06
Personal Relationships, Week 16 (n=310,302)0.6 ± 0.060.3 ± 0.06
Personal Relationships, Week 24 (n=271,276)0.6 ± 0.070.3 ± 0.05
Symptoms and Feelings, Baseline (n=331,333)3.9 ± 0.093.9 ± 0.08
Symptoms and Feelings, Week 4 (n=326,330)2.1 ± 0.071.6 ± 0.07
Symptoms and Feelings, Week 8 (n=321,319)1.8 ± 0.081.2 ± 0.07
Symptoms and Feelings, Week 16 (n=310,303)1.7 ± 0.081.1 ± 0.08
Symptoms and Feelings, Week 24 (n=273,277)1.7 ± 0.091.0 ± 0.08
Leisure, Baseline (n=331,333)2.1 ± 0.112.2 ± 0.11
Leisure, Week 4 (n=326,330)1.1 ± 0.090.8 ± 0.07
Leisure, Week 8 (n=321,320)0.9 ± 0.080.5 ± 0.06
Leisure, Week 16 (n=310,303)0.7 ± 0.070.4 ± 0.06
Leisure, Week 24 (n=272,277)0.8 ± 0.080.4 ± 0.05
Work and School, Baseline (n=330,333)0.9 ± 0.060.9 ± 0.06
Work and School, Week 4 (n=326,330)0.5 ± 0.050.3 ± 0.04
Work and School, Week 8 (n=321,319)0.3 ± 0.040.2 ± 0.03
Work and School, Week 16 (n=309,303)0.3 ± 0.040.2 ± 0.03
Work and School, Week 24 (n=273,277)0.4 ± 0.040.1 ± 0.03
Treatment, Baseline (n=331,332)1.1 ± 0.061.2 ± 0.06
Treatment, Week 4 (n=326,330)0.6 ± 0.040.5 ± 0.04
Treatment, Week 8 (n=321,320)0.5 ± 0.040.4 ± 0.03
Treatment, Week 16 (n=310,303)0.5 ± 0.040.3 ± 0.04
Treatment, Week 24 (n=272,277)0.6 ± 0.050.2 ± 0.03
SecondaryMean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · score on a scale
Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)
score on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Daily Activities, Baseline (n=31,82,45,133)0.5 ± 0.180.3 ± 0.070.2 ± 0.070.3 ± 0.07
Daily Activities, Week 4 (n=30,82,43,127)0.8 ± 0.300.8 ± 0.140.3 ± 0.091.2 ± 0.14
Daily Activities, Week 8 (n=30,68,43,104)0.6 ± 0.251.1 ± 0.190.4 ± 0.131.2 ± 0.17
Daily Activities, Week 12 (n=28,52,41,83)0.6 ± 0.230.9 ± 0.150.3 ± 0.101.1 ± 0.17
Daily Activities, Week 16 (n=28,44,38,68)0.6 ± 0.221.2 ± 0.210.4 ± 0.121.3 ± 0.21
Personal Relationships, Baseline (n=31,82,45,133)0.3 ± 0.130.2 ± 0.060.2 ± 0.080.1 ± 0.04
Personal Relationships, Week 4 (n=30,82,43,126)0.4 ± 0.190.6 ± 0.110.1 ± 0.050.6 ± 0.10
Personal Relationships, Week 8 (n=30,68,43,103)0.4 ± 0.220.8 ± 0.170.1 ± 0.070.9 ± 0.14
Personal Relationships, Week 12 (n=28,52,41,83)0.4 ± 0.230.6 ± 0.150.1 ± 0.050.7 ± 0.13
Personal Relationships, Week 16 (n=28,44,38,68)0.4 ± 0.230.5 ± 0.160.2 ± 0.070.8 ± 0.17
Symptoms and Feelings, Baseline (n=31,82,45,133)1.1 ± 0.250.8 ± 0.100.5 ± 0.100.6 ± 0.08
Symptoms and Feelings, Week 4 (n=30,82,43,127)1.3 ± 0.302.0 ± 0.190.5 ± 0.132.2 ± 0.16
Symptoms and Feelings, Week 8 (n=30,68,43,104)1.1 ± 0.242.2 ± 0.190.7 ± 0.162.3 ± 0.18
Symptoms and Feelings, Week 12 (n=28,52,41,83)1.1 ± 0.282.1 ± 0.191.0 ± 0.192.0 ± 0.18
Symptoms and Feelings, Week 16 (n=28,44,38,68)1.4 ± 0.311.9 ± 0.191.0 ± 0.162.2 ± 0.21
Leisure, Baseline (n=31,82,45,133)0.3 ± 0.120.2 ± 0.070.2 ± 0.080.2 ± 0.05
Leisure, Week 4 (n=30,82,42,127)0.5 ± 0.230.6 ± 0.110.1 ± 0.080.9 ± 0.13
Leisure, Week 8 (n=30,68,43,104)0.5 ± 0.150.8 ± 0.180.2 ± 0.110.9 ± 0.15
Leisure, Week 12 (n=28,52,41,83)0.5 ± 0.180.5 ± 0.140.2 ± 0.070.7 ± 0.14
Leisure, Week 16 (n=28,44,37,68)0.5 ± 0.170.5 ± 0.150.1 ± 0.070.9 ± 0.17
Work and School, Baseline (n=31,82,45,133)0.1 ± 0.040.1 ± 0.050.0 ± 0.020.1 ± 0.02
Work and School, Week 4 (n=30,82,43,127)0.1 ± 0.060.3 ± 0.070.0 ± 0.020.5 ± 0.09
Work and School, Week 8 (n=30,68,43,104)0.2 ± 0.080.3 ± 0.090.0 ± 0.030.5 ± 0.09
Work and School, Week 12 (n=28,52,41,83)0.2 ± 0.130.2 ± 0.060.1 ± 0.050.4 ± 0.09
Work and School, Week 16 (n=28,44,38,68)0.3 ± 0.130.3 ± 0.080.0 ± 0.030.4 ± 0.10
Treatment, Baseline (n=31,82,45,133)0.3 ± 0.100.1 ± 0.040.2 ± 0.050.1 ± 0.03
Treatment, Week 4 (n=30,82,43,127)0.3 ± 0.100.4 ± 0.070.2 ± 0.060.5 ± 0.08
Treatment, Week 8 (n=30,68,43,104)0.3 ± 0.100.5 ± 0.090.1 ± 0.050.6 ± 0.09
Treatment, Week 12 (n=28,52,41,83)0.4 ± 0.140.4 ± 0.090.2 ± 0.090.5 ± 0.08
Treatment, Week 16 (n=28,44,38,68)0.3 ± 0.120.6 ± 0.110.2 ± 0.070.6 ± 0.11
SecondaryMean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · score on a scale
Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Daily Activities, Baseline (n=27,75,42,120)0.7 ± 0.231.5 ± 0.190.4 ± 0.121.8 ± 0.17
Daily Activities, Week 4 (n=27,74,42,119)0.6 ± 0.240.9 ± 0.140.5 ± 0.140.8 ± 0.11
Daily Activities, Week 8 (n=26,71,41,118)0.9 ± 0.330.7 ± 0.120.4 ± 0.140.5 ± 0.09
Daily Activities, Week 16 (n=22,65,39,101)0.7 ± 0.270.8 ± 0.140.4 ± 0.150.5 ± 0.10
Personal Relationships, Baseline (n=27,75,42,120)0.4 ± 0.230.9 ± 0.160.1 ± 0.061.2 ± 0.15
Personal Relationships, Week 4 (n=27,74,42,119)0.4 ± 0.240.5 ± 0.100.2 ± 0.090.5 ± 0.10
Personal Relationships, Week 8 (n=26,71,41,118)0.4 ± 0.250.2 ± 0.070.3 ± 0.120.3 ± 0.09
Personal Relationships, Week 16 (n=22,66,39,101)0.2 ± 0.160.3 ± 0.090.1 ± 0.110.2 ± 0.06
Symptoms and Feelings, Baseline (n=27,75,42,120)1.4 ± 0.322.6 ± 0.191.1 ± 0.202.9 ± 0.18
Symptoms and Feelings, Week 4 (n=27,74,42,119)1.4 ± 0.271.6 ± 0.151.0 ± 0.201.4 ± 0.11
Symptoms and Feelings, Week 8 (n=26,71,41,118)1.5 ± 0.361.5 ± 0.141.0 ± 0.181.0 ± 0.12
Symptoms and Feelings, Week 16 (n=22,66,39,101)1.2 ± 0.271.5 ± 0.150.9 ± 0.221.0 ± 0.12
Leisure, Baseline (n=27,75,42,120)0.5 ± 0.180.9 ± 0.180.1 ± 0.061.4 ± 0.16
Leisure, Week 4 (n=27,74,41,119)0.4 ± 0.170.6 ± 0.130.2 ± 0.090.6 ± 0.10
Leisure, Week 8 (n=26,71,41,118)0.5 ± 0.220.4 ± 0.080.3 ± 0.100.4 ± 0.09
Leisure, Week 16 (n=22,66,39,101)0.4 ± 0.240.4 ± 0.100.3 ± 0.130.4 ± 0.09
Work and School, Baseline (n=27,75,42,120)0.3 ± 0.140.5 ± 0.090.1 ± 0.040.6 ± 0.09
Work and School, Week 4 (n=27,74,42,119)0.2 ± 0.120.2 ± 0.080.1 ± 0.040.2 ± 0.05
Work and School, Week 8 (n=26,71,41,118)0.2 ± 0.140.1 ± 0.040.0 ± 0.030.2 ± 0.05
Work and School, Week 16 (n =22,66,39,101)0.2 ± 0.140.2 ± 0.050.2 ± 0.090.1 ± 0.05
Treatment, Baseline (n=27,75,42,120)0.3 ± 0.130.7 ± 0.100.3 ± 0.090.9 ± 0.09
Treatment, Week 4 (n=27,74,42,119)0.3 ± 0.100.4 ± 0.080.2 ± 0.090.4 ± 0.05
Treatment, Week 8 (n=26,71,41,118)0.3 ± 0.140.3 ± 0.060.1 ± 0.050.3 ± 0.05
Treatment, Week 16 (n=22,66,39,101)0.2 ± 0.090.2 ± 0.060.2 ± 0.080.3 ± 0.05
SecondaryMean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Daily Activities, Week 4 (n=325,328)-1.2 ± 0.09-1.6 ± 0.09
Daily Activities, Week 8 (n=320,318)-1.5 ± 0.10-1.9 ± 0.10
Daily Activities, Week 16 (n=309,301)-1.7 ± 0.10-2.0 ± 0.10
Daily Activities, Week 24 (n=272,275)-1.6 ± 0.11-2.0 ± 0.11
Personal Relationships, Week 4 (n=326,327)-0.8 ± 0.08-1.0 ± 0.09
Personal Relationships, Week 8 (n=321,316)-1.0 ± 0.08-1.3 ± 0.09
Personal Relationships, Week 16 (n=310,300)-1.1 ± 0.09-1.3 ± 0.10
Personal Relationships, Week 24 (n=271,274)-1.0 ± 0.10-1.3 ± 0.10
Symptoms and Feelings, Week 4 (n=326,328)-1.9 ± 0.08-2.3 ± 0.08
Symptoms and Feelings, Week 8 (n=321,317)-2.2 ± 0.09-2.7 ± 0.09
Symptoms and Feelings, Week 18 (n=310,301)-2.2 ± 0.09-2.8 ± 0.10
Symptoms and Feelings, Week 24 (n=273,275)-2.1 ± 0.11-2.9 ± 0.10
Leisure, Week 4 (n=326,328)-1.0 ± 0.10-1.4 ± 0.10
Leisure, Week 16 (n=310,301)-1.4 ± 0.11-1.7 ± 0.11
Leisure, Week 8 (n=321,318)-1.2 ± 0.10-1.7 ± 0.10
Leisure, Week 24 (n=272,275)-1.3 ± 0.12-1.8 ± 0.12
Work and School, Week 4 (n=325,328)-0.4 ± 0.05-0.6 ± 0.06
Work and School, Week 8 (n=320,317)-0.6 ± 0.05-0.7 ± 0.06
Work and School, Week 16 (n=308,301)-0.6 ± 0.06-0.7 ± 0.06
Work and School, Week 24 (n=272,275)-0.5 ± 0.06-0.7 ± 0.06
Treatment, Week 4 (n=326,327)-0.5 ± 0.06-0.7 ± 0.05
Treatment, Week 8 (n=321,317)-0.6 ± 0.06-0.8 ± 0.06
Treatment, Week 16 (n=310,300)-0.6 ± 0.06-0.9 ± 0.06
Treatment, Week 24 (n=272,274)-0.5 ± 0.06-1.0 ± 0.06
SecondaryMean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)
scores on a scaleCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Daily Activities, Week 4 (n=30,82,43,127)0.3 ± 0.220.5 ± 0.140.1 ± 0.080.9 ± 0.13
Daily Activities, Week 8 (n=30,68,43,104)0.1 ± 0.090.8 ± 0.170.2 ± 0.131.0 ± 0.17
Daily Activities, Week 12 (n=28,52,41,83)0.2 ± 0.130.7 ± 0.140.1 ± 0.110.9 ± 0.17
Daily Activities, Week 16 (n=28,44,38,68)0.2 ± 0.120.9 ± 0.190.2 ± 0.101.1 ± 0.22
Personal Relationships, Week 4 (n=30,82,43,126)0.0 ± 0.110.4 ± 0.10-0.1 ± 0.080.5 ± 0.09
Personal Relationships, Week 8 (n=30,68,43,103)0.1 ± 0.150.6 ± 0.15-0.1 ± 0.090.8 ± 0.13
Personal Relationships, Week 12 (n=28,52,41,83)0.1 ± 0.140.4 ± 0.14-0.1 ± 0.090.6 ± 0.13
Personal Relationships, Week 16 (n=28,44,38,68)0.1 ± 0.150.3 ± 0.15-0.1 ± 0.100.8 ± 0.17
Symptoms and Feelings, Week 4 (n=30,82,43,127)0.2 ± 0.251.3 ± 0.170.1 ± 0.131.7 ± 0.14
Symptoms and Feelings, Week 8 (n=30,68,43,104)0.0 ± 0.131.5 ± 0.170.2 ± 0.171.8 ± 0.16
Symptoms and Feelings, Week 12 (n=28,52,41,83)0.1 ± 0.191.4 ± 0.180.5 ± 0.191.6 ± 0.18
Symptoms and Feelings, Week 16 (n=28,44,38,68)0.4 ± 0.211.3 ± 0.220.5 ± 0.141.8 ± 0.21
Leisure, Week 4 (n=30,82,42,127)0.2 ± 0.220.3 ± 0.11-0.1 ± 0.090.7 ± 0.12
Leisure, Week 8 (n=30,68,43,104)0.1 ± 0.100.5 ± 0.160.0 ± 0.100.8 ± 0.15
Leisure, Week 12 (n=28,52,41,83)0.2 ± 0.120.4 ± 0.110.0 ± 0.090.6 ± 0.15
Leisure, Week 16 (n=28,44,37,68)0.2 ± 0.120.4 ± 0.12-0.1 ± 0.080.8 ± 0.18
Work and School, Week 4 (n=30,82,43,127)0.0 ± 0.60.2 ± 0.070.0 ± 0.000.5 ± 0.08
Work and School, Week 8 (n=30,68,43,104)0.1 ± 0.060.2 ± 0.090.0 ± 0.020.4 ± 0.08
Work and School, Week 12 (n=28,52,41,83)0.1 ± 0.080.1 ± 0.070.1 ± 0.040.3 ± 0.09
Work and School, Week 16 (n=28,44,38,68)0.2 ± 0.100.2 ± 0.090.0 ± 0.000.4 ± 0.10
Treatment, Week 4 (n=30,82,43,127)0.0 ± 0.070.2 ± 0.060.1 ± 0.060.4 ± 0.07
Treatment, Week 8 (n=30,68,43,104)0.0 ± 0.060.4 ± 0.090.0 ± 0.060.6 ± 0.08
Treatment, Week 12 (n=28,52,41,83)0.1 ± 0.110.3 ± 0.70.0 ± 0.090.4 ± 0.09
Treatment, Week 16 (n=28,44,38,68)0.0 ± 0.100.5 ± 0.110.1 ± 0.050.5 ± 0.10
SecondaryMean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Daily Activities, Week 4 (n=27,74,42,119)0.0 ± 0.06-0.7 ± 0.120.1 ± 0.11-1.0 ± 0.13
Daily Activities, Week 8 (n=26,71,41,118)0.2 ± 0.15-0.7 ± 0.130.0 ± 0.14-1.3 ± 0.15
Daily Activities, Week 16 (n=22,65,39,101)0.4 ± 0.23-0.7 ± 0.20-0.1 ± 0.18-1.3 ± 0.18
Personal Relationships, Week 4 (n=27,74,42,119)0.0 ± 0.05-0.4 ± 0.110.1 ± 0.08-0.7 ± 0.13
Personal Relationships, Week 8 (n=26,71,41,118)0.0 ± 0.07-0.6 ± 0.130.1 ± 0.13-0.8 ± 0.14
Personal Relationships, Week 16 (n=22,66,39,101)0.0 ± 0.11-0.6 ± 0.140.1 ± 0.12-0.9 ± 0.15
Symptoms and Feelings, Week 4 (n=27,74,42,119)0.0 ± 0.14-1.0 ± 0.13-0.1 ± 0.13-1.5 ± 0.15
Symptoms and Feelings, Week 8 (n=26,71,41,118)0.0 ± 0.14-1.1 ± 0.17-0.1 ± 0.18-1.8 ± 0.18
Symptoms and Feelings, Week 16 (n=22,66,39,101)0.0 ± 0.20-1.0 ± 0.20-0.2 ± 0.21-1.9 ± 0.19
Leisure, Week 4 (n=27,74,41,119)-0.1 ± 0.08-0.3 ± 0.140.1 ± 0.06-0.8 ± 0.13
Leisure, Week 8 (n=26,71,41,118)0.0 ± 0.13-0.4 ± 0.130.1 ± 0.10-1.0 ± 0.15
Leisure, Week 16 (n=22,66,39,101)0.0 ± 0.28-0.4 ± 0.170.2 ± 0.12-1.1 ± 0.18
Work and School, Week 4 (n=27,74,42,119)0.0 ± 0.06-0.2 ± 0.070.0 ± 0.03-0.4 ± 0.08
Work and School, Week 8 (n=26,71,41,118)0.0 ± 0.7-0.3 ± 0.090.0 ± 0.06-0.4 ± 0.09
Work and School, Week 16 (n=22,66,39,101)0.0 ± 0.07-0.3 ± 0.100.1 ± 0.09-0.5 ± 0.09
Treatment, Week 4 (n=27,74,42,119)0.0 ± 0.08-0.2 ± 0.080.0 ± 0.07-0.6 ± 0.07
Treatment, Week 8 (n=26,71,41,118)0.0 ± 0.07-0.3 ± 0.08-0.2 ± 0.09-0.07 ± 0.09
Treatment, Week 16 (n=22,66,39,101)0.0 ± 0.08-0.3 ± 0.09-0.1 ± 0.11-0.7 ± 0.10
SecondaryPercentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 459.86 (54.16 to 65.56)75.44 (70.41 to 80.48)
Week 870.42 (65.11 to 75.73)80.78 (76.18 to 85.39)
Week 1670.77 (65.49 to 76.06)79.00 (74.24 to 83.77)
Week 2459.86 (54.16 to 65.56)72.95 (67.76 to 78.15)
SecondaryPercentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 40.0016.6733.330.00
Week 80.000.000.0011.11
Week 1211.110.0066.6711.11
Week 160.008.3333.3311.11
SecondaryPercentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 40.00 (0.00 to 0.00)47.50 (32.02 to 62.98)0.00 (0.00 to 0.00)65.79 (55.12 to 76.46)
Week 812.50 (0.00 to 35.42)55.00 (39.58 to 70.42)25.00 (0.00 to 55.01)77.63 (68.26 to 87.00)
Week 1612.50 (0.00 to 35.42)47.50 (32.02 to 62.98)12.50 (0.00 to 35.42)64.47 (53.71 to 75.23)
SecondaryPercentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 413.44 (9.70 to 17.17)26.88 (22.02 to 31.73)
Week 825.94 (21.14 to 30.74)41.88 (36.47 to 47.28)
Week 1630.94 (25.87 to 36.00)53.13 (47.66 to 58.59)
Week 2430.63 (25.57 to 35.68)50.00 (44.52 to 55.48)
SecondaryPercentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline0.000.000.000.00
Week 47.694.0041.6712.90
Week 87.690.0033.339.68
Week 127.690.008.339.68
Week 167.690.0016.679.68
SecondaryPercentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 416.67 (0.00 to 37.75)24.59 (13.78 to 35.40)37.50 (13.78 to 61.22)24.73 (15.96 to 33.50)
Week 816.67 (0.00 to 37.75)26.23 (15.19 to 37.27)31.25 (8.54 to 53.96)40.86 (30.87 to 50.85)
Week 1616.67 (0.00 to 37.75)29.51 (18.06 to 40.95)37.50 (13.78 to 61.22)40.86 (30.87 to 50.85)
SecondaryPercentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.

Time frame:
Baseline and Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline, No effect (0-1) (n=330,333)3.0 ± 3.03.9 ± 3.9
Baseline, Small effect (2-5;n=330,333)15.2 ± 15.217.1 ± 17.1
Baseline, Moderate effect (6-10;n=330,333)27.0 ± 27.021.3 ± 21.3
Baseline, Very large effect (11-20;n=330,333)39.1 ± 39.141.7 ± 41.7
Baseline, Extremely large effect (21-30;n=330,333)15.8 ± 15.815.9 ± 15.9
Week 4, No effect (0-1) (n=326,330)15.6 ± 15.629.4 ± 29.4
Week 4, Small effect (2-5;n=326,330)35.9 ± 35.937.3 ± 37.3
Week 4, Moderate effect (6-10;n=326,330)25.8 ± 25.822.1 ± 22.1
Week 4, Very large effect (11-20;n=326,330)18.7 ± 18.79.7 ± 9.7
Week 4, Extremely large effect (21-30;n=326,330)4.0 ± 4.01.5 ± 1.5
Week 8, No effect (0-1) (n=321,319)28.0 ± 28.045.5 ± 45.5
Week 8, Small effect (2-5;n=321,319)34.0 ± 34.034.8 ± 34.8
Week 8, Moderate effect (6-10;n=321,319)23.7 ± 23.712.5 ± 12.5
Week 8, Very large effect (11-20;n=321,319)11.8 ± 11.85.0 ± 5.0
Week 8, Extremely large effect (21-30;n=321,319)2.5 ± 2.52.2 ± 2.2
Week 16, No effect (0-1) (n=310,303)34.2 ± 34.259.4 ± 59.4
Week 16, Small effect (2-5;n=310,303)34.5 ± 34.522.1 ± 22.1
Week 16, Moderate effect (6-10;n=310,303)18.4 ± 18.410.6 ± 10.6
Week 16, Very large effect (11-20;n=310,303)11.0 ± 11.06.3 ± 6.3
Week 16, Extremely large effect (21-30;n=310,303)1.9 ± 1.91.7 ± 1.7
Week 24, No effect (0-1) (n=273,277)38.1 ± 38.161.0 ± 61.0
Week 24, Small effect (2-5;n=273,277)27.1 ± 27.124.9 ± 24.9
Week 24, Moderate effect (6-10;n=273,277)19.0 ± 19.09.0 ± 9.0
Week 24, Very large effect (11-20;n=273,277)12.8 ± 12.83.2 ± .32
Week 24, Extremely large effect (21-30;n=273,277)2.9 ± 2.91.8 ± 1.8
SecondaryPercentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Week 460.1 (54.5 to 65.9)76.6 (71.5 to 81.4)
Week 877.4 (72.4 to 82.2)88.7 (84.6 to 92.2)
Week 1685.7 (81.3 to 89.6)94.9 (91.6 to 97.2)
Week 2491.9 (83.2 to 97.1)96.1 (92.9 to 98.1)
SecondaryMedian Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Median · weeks
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
weeksCP-690,550 5 mg (Period A)CP-690,550 10 mg BID (Period A)
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)4.4 (4.3 to 4.7)4.1 (4.1 to 4.3)
SecondaryPercentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 40.0 (0.0 to 0.0)47.5 (33.5 to 63.9)0.0 (0.0 to 0.0)65.8 (55.2 to 76.2)
Week 812.5 (1.9 to 61.3)72.5 (58.3 to 85.1)25.0 (6.9 to 68.5)80.9 (71.3 to 88.9)
Week 1612.5 (1.9 to 61.3)81.3 (67.3 to 91.9)25.0 (6.9 to 68.5)88.4 (79.1 to 94.8)
SecondaryMedian Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)

The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.

Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Median · weeks
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)
weeksCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)NA (NA to NA)8.1 (4.7 to 8.6)NA (NA to NA)4.4 (4.3 to 5.7)
SecondaryMean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 24 (Period A)
Reported as:
Mean · score on a scale
Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline Physical Health Score (n=330,334)48.1 ± 0.547.8 ± 0.5
Week 24 Physical Health Score (n=273,276)50.5 ± 0.552.9 ± 0.5
Baseline Mental Health Score (n=330,334)45.2 ± 0.746.1 ± 0.6
Week 24 Mental Health Score (n=273,276)48.9 ± 0.651.2 ± 0.6
SecondaryMean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 56 (Period C)
Reported as:
Mean · score on a scale
Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline Physical Health Score (n=27,75,42,120)51.8 ± 1.849.9 ± 1.153.8 ± 1.149.7 ± 0.8
Week 56 Physical Health Score (n=22,65,34,98)52.9 ± 1.852.7 ± 1.052.9 ± 1.451.2 ± 0.9
Baseline Mental Health Score (n=27,75,42,120)51.7 ± 1.951.0 ± 1.150.8 ± 1.948.3 ± 1.0
Week 56 Mental Health Score (n=22,65,34,98)50.8 ± 1.850.9 ± 1.252.4 ± 1.553.7 ± 0.8
SecondaryMean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame:
Week 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Physical Health Score1.9 ± 0.55.2 ± 0.5
Mental Health Score3.2 ± 0.64.9 ± 0.6
SecondaryMean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.

Time frame:
Week 56 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Physical Health Score-0.9 ± 1.22.7 ± 0.8-1.0 ± 0.81.8 ± 0.9
Mental Health Score-1.6 ± 1.20.1 ± 1.00.5 ± 1.94.9 ± 1.0
SecondaryMean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 24 (Period A)
Reported as:
Mean · score on a scale
Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline Physical Functioning (n=331,335)48.3 ± 0.648.0 ± 0.6
Week 24 Physical Functioning (n=273,276)50.7 ± 0.652.7 ± 0.5
Baseline Role Physical (n=331,335)47.2 ± 0.647.6 ± 0.6
Week 24 Role Physical (n=273,276)50.2 ± 0.653.1 ± 0.5
Baseline Bodily Pain (n=331,334)44.7 ± 0.644.2 ± 0.7
Week 24 Bodily Pain (n=273,276)50.0 ± 0.653.2 ± 0.5
Baseline General Health (n=330,335)48.1 ± 0.548.9 ± 0.5
Week 24 General Health (n=273,276)49.0 ± 0.650.3 ± 0.5
Baseline Vitality (n=331,334)49.2 ± 0.649.3 ± 0.5
Week 24 Vitality (n=273,276)51.0 ± 0.654.2 ± 0.5
Baseline Social Functioning (n=331,334)44.6 ± 0.744.6 ± 0.7
Week 24 Social Functioning (n=273,276)48.9 ± 0.651.7 ± 0.5
Baseline Role Emotional (n=331,335)45.5 ± 0.745.8 ± 0.7
Week 24 Role Emotional (n=273,276)49.2 ± 0.651.2 ± 0.5
Baseline Mental Health (n=331,334)45.0 ± 0.646.4 ± 0.6
Week 24 Mental Health (n=273,276)48.8 ± 0.651.0 ± 0.6
Baseline Health Transition Score (n=331,334)3.0 ± 0.03.1 ± 0.0
Week 24 Health Transition Score (n=272, 276)2.8 ± 0.02.8 ± 0.0
SecondaryMean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.

Time frame:
Baseline and Week 56 (Period C)
Reported as:
Mean · score on a scale
Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline Physical Functioning (n=27,75,42,120)50.7 ± 1.851.3 ± 1.052.7 ± 1.351.1 ± 0.8
Week 56 Physical Functioning (n=22,65,34,98)51.7 ± 1.952.4 ± 1.152.3 ± 1.651.3 ± 0.9
Baseline Role Physical (n=27,75,42,120)51.2 ± 1.650.5 ± 1.053.3 ± 1.149.1 ± 0.9
Week 56 Role Physical (n=22,65,34,98)52.5 ± 1.651.4 ± 1.254.2 ± 1.151.9 ± 0.8
Baseline Bodily Pain (n=27,75,42,120)52.8 ± 1.948.8 ± 1.254.1 ± 1.547.1 ± 1.1
Week 56 Bodily Pain (n=22,65,34,98)53.9 ± 2.152.7 ± 1.053.5 ± 1.852.7 ± 0.9
Baseline General Health (n=27,75,42,120)52.0 ± 1.749.6 ± 1.151.9 ± 1.448.7 ± 0.9
Week 56 General Health (n=22,65,34,98)51.5 ± 1.851.8 ± 1.051.1 ± 1.450.7 ± 0.8
Baseline Vitality (n=27,75,42,120)53.8 ± 2.252.2 ± 1.154.1 ± 1.551.3 ± 0.9
Week 56 Vitality (n=22,65,34,98)52.2 ± 2.253.2 ± 1.154.8 ± 1.754.3 ± 0.9
Baseline Social Functioning (n=27,75,42,120)51.2 ± 1.849.7 ± 1.051.5 ± 1.448.1 ± 1.0
Week 56 Social Functioning (n=22,65,34,98)52.2 ± 1.652.4 ± 1.051.3 ± 1.753.2 ± 0.6
Baseline Role Emotional (n=27,75,42,120)51.1 ± 1.851.6 ± 0.850.3 ± 1.748.0 ± 1.0
Week 56 Role Emotional (n=22,65,34,98)50.5 ± 1.850.0 ± 1.352.9 ± 1.153.0 ± 0.6
Baseline Mental Health (n=27,75,42,120)51.2 ± 2.050.2 ± 1.151.6 ± 1.848.4 ± 1.0
Week 56 Mental Health (n=22,65,34,98)51.1 ± 1.851.1 ± 1.252.2 ± 1.552.7 ± 0.8
Baseline Health Transition (n=27,75,42,120)2.9 ± 0.13.1 ± 0.12.8 ± 0.13.0 ± 0.1
Week 56 Health Transition (n=22,65,34,98)3.0 ± 0.12.7 ± 0.12.8 ± 0.12.8 ± 0.1
SecondaryMean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Week 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Physical Functioning (n=273,276)1.8 ± 0.54.6 ± 0.5
Role Physical (n=273,276)2.6 ± 0.75.6 ± 0.6
Bodily Pain (n=273,275)4.5 ± 0.79.0 ± 0.7
General Health (n=273,276)0.7 ± 0.51.7 ± 0.4
Vitality (n=273,275)1.3 ± 0.54.8 ± 0.5
Social Functioning (n=273,275)3.7 ± 0.76.6 ± 0.7
Role Emotional (n=273,276)3.2 ± 0.85.6 ± 0.7
Mental Health (n=273,275)3.4 ± 0.64.4 ± 0.6
Health Transition (n=272,275)-0.2 ± 0.1-0.2 ± 0.0
SecondaryMean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)

The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Week 56 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Physical Functioning-0.4 ± 0.71.2 ± 0.7-0.5 ± 0.70.7 ± 0.9
Role Physical-0.7 ± 0.91.2 ± 1.10.2 ± 0.82.7 ± 0.9
Bodily Pain-1.6 ± 1.63.8 ± 1.1-1.1 ± 1.46.0 ± 1.2
General Health-0.7 ± 0.91.9 ± 0.8-1.1 ± 0.91.6 ± 0.8
Vitality-3.5 ± 1.31.1 ± 0.90.2 ± 1.63.1 ± 1.0
Social Functioning-1.5 ± 0.72.6 ± 1.1-1.3 ± 1.94.7 ± 1.0
Role Emotional-1.4 ± 1.0-1.3 ± 1.21.9 ± 1.64.6 ± 1.0
Mental Health-0.1 ± 1.51.1 ± 0.9-0.5 ± 1.54.1 ± 1.0
Health Transition Score-0.0 ± 0.1-0.3 ± 0.10.1 ± 0.1-0.2 ± 0.1
SecondaryPercentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe

Time frame:
Baseline and Weeks 4, 8, 16 and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Baseline, Clear (n=330,335)0.00.0
Baseline, Almost clear (n=330,335)0.00.3
Baseline, Mild (n=330,335)3.61.2
Baseline, Moderate (n=330,335)30.334.6
Baseline Severe (n=330,335)66.163.9
Week 4, Clear (n=325,331)0.31.2
Week 4, Almost Clear (n=325,331)11.720.2
Week 4, Mild (n=325,331)24.930.5
Week 4, Moderate (n=325,331)40.637.8
Week 4, Severe (n=325,331)22.510.3
Week 8, Clear (n=320,321)1.95.9
Week 8, Almost Clear (n=320,321)21.341.4
Week 8, Mild (n=320,321)31.925.2
Week 8, Moderate (n=320,321)30.022.4
Week 8, Severe (n=320,321)15.05.0
Week 16, Clear (n=310,303)5.516.8
Week 16, Almost Clear (n=310,303)27.143.6
Week 16, Mild (n=310,303)30.620.8
Week 16, Moderate (n=310,303)27.711.9
Week 16, Severe (n=310,303)9.06.9
Week 24, Clear (n=273,277)8.120.9
Week 24, Almost Clear (n=273,277)27.841.5
Week 24, Mild (n=273,277)23.820.2
Week 24, Moderate (n=273,277)30.013.4
Week 24, Severe (n=273,277)10.34.0
SecondaryPercentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.

Time frame:
Baseline and Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Baseline, Clear (n=31,82,45,133)16.119.524.435.3
Baseline, Almost Clear (n=31,82,45,133)45.261.062.246.6
Baseline, Mild (n=31,82,45,133)25.812.211.115.0
Baseline, Moderate (n=31,82,45,133)12.97.32.23.0
Baseline, Severe (n=31,82,45,133)0.00.00.00.0
Week 4, Clear (n=30,82,43,126)23.38.523.311.1
Week 4, Almost Clear (n=30,82,43,126)43.334.158.133.3
Week 4, Mild (n=30,82,43,126)23.330.511.617.5
Week 4, Moderate (n=30,82,43,126)6.715.97.027.0
Week 4, Severe (n=30,82,43,126)3.311.00.011.1
Week 8, Clear (n=30,68,43,104)23.37.420.95.8
Week 8, Almost Clear (n=30,68,43,104)30.027.948.829.8
Week 8, Mild (n=30,68,43,104)36.723.523.326.0
Week 8, Moderate (n=30,68,43,104)10.026.57.023.1
Week 8, Severe (n=30,68,43,104)0.014.70.015.4
Week 12, Clear (n=28,52,41,83)17.91.914.64.8
Week 12, Almost Clear (n=28,52,41,83)35.719.258.532.5
Week 12, Mild (n=28,52,41,83)32.136.522.024.1
Week 12, Moderate (n=28,52,41,83)10.728.84.924.1
Week 12, Severe (n=28,52,41,83)3.613.50.014.5
Week 16, Clear (n=27,45,38,68)22.24.418.47.4
Week 16, Almost Clear (n=27,45,38,68)33.328.952.625.0
Week 16, Mild (n=27,45,38,68)18.522.221.125.0
Week 16, Moderate (n=27,45,38,68)25.933.37.930.9
Week 16, Severe (n=27,45,38,68)0.011.10.011.8
SecondaryPercentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline, Clear (n=27,75,42,120)22.22.719.05.0
Baseline, Almost Clear (n=27,75,42,120)33.318.750.018.3
Baseline, Mild (n=27,75,42,120)18.518.716.717.5
Baseline, Moderate (n=27,75,42,120)25.937.314.333.3
Baseline, Severe (n=27,75,42,120)0.022.70.025.8
Week 4, Clear (n=27,74,42,118)18.55.419.010.2
Week 4, Almost Clear (n=27,74,42,118)37.023.050.041.5
Week 4, Mild (n=27,74,42,118)33.341.911.923.7
Week 4, Moderate (n=27,74,42,118)11.125.714.320.3
Week 4, Severe (n=27,74,42,118)0.04.14.84.2
Week 8, Clear (n=26,71,41,118)19.27.019.515.3
Week 8, Almost Clear (n=26,71,41,118)26.936.651.246.6
Week 8, Mild (n=26,71,41,118)30.838.019.524.6
Week 8, Moderate (n=26,71,41,118)19.216.97.39.3
Week 8, Severe (n=26,71,41,118)3.81.42.44.2
Week 16, Clear (n=22,65,38,101)13.610.818.420.8
Week 16, Almost Clear (n=22,65,38,101)31.843.157.947.5
Week 16, Mild (n=22,65,38,101)36.427.710.518.8
Week 16, Moderate (n=22,65,38,101)13.613.85.310.9
Week 16, Severe (n=22,65,38,101)4.54.67.92.0
SecondaryPercentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 411.78 (8.31 to 15.26)21.19 (16.82 to 25.57)
Week 822.36 (17.87 to 26.84)45.37 (40.04 to 50.70)
Week 1630.51 (25.55 to 35.47)54.63 (49.30 to 59.96)
Week 2429.61 (24.69 to 34.53)51.64 (46.29 to 56.99)
SecondaryPercentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

Time frame:
Baseline and Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline (n=14,63,17,100)14.29 (0.00 to 32.62)6.35 (0.33 to 12.37)23.53 (3.37 to 43.69)8.00 (2.68 to 13.32)
Week 4 (n=14,63,17,100)21.43 (0.00 to 42.92)19.05 (9.35 to 28.74)35.29 (12.58 to 58.01)42.00 (32.33 to 51.67)
Week 8 (n=14,63,17,100)21.43 (0.00 to 42.92)34.92 (23.15 to 46.69)41.18 (17.78 to 64.57)54.00 (44.23 to 63.77)
Week 16 (n=14,63,17,100)21.43 (0.00 to 42.92)41.27 (29.11 to 53.43)58.82 (35.43 to 82.22)53.00 (43.22 to 62.78)
SecondaryPercentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B

The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.

Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Week 494.7 (68.1 to 99.2)50.7 (38.0 to 62.0)82.0 (65.9 to 91.0)55.5 (45.5 to 64.4)
Week 889.2 (63.1 to 97.2)32.8 (21.6 to 44.4)71.4 (54.3 to 83.0)33.3 (24.5 to 42.4)
Week 1277.3 (50.1 to 90.8)21.3 (12.2 to 32.2)68.8 (51.6 to 80.9)24.2 (16.4 to 32.9)
Week 1677.3 (50.1 to 90.8)16.0 (7.5 to 27.3)0.0 (NA to NA)0.0 (NA to NA)
SecondaryMean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Mean · score on a scale
Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Utility Score, Baseline (n=329,332)0.7 ± 0.00.7 ± 0.0
Utility Score, Week 24 (n=270,272)0.8 ± 0.00.9 ± 0.0
VAS, Baseline (n=329,332)69.9 ± 1.370.6 ± 1.3
VAS, Week 24 (n=269,274)75.6 ± 1.280.3 ± 1.0
SecondaryMean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and Week 56 (Period C)
Reported as:
Mean · score on a scale
Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline Utility Score (n=27,75,42,120)0.8 ± 0.00.8 ± 0.00.9 ± 0.00.8 ± 0.0
Week 56 Utility Score (n=22,65,34,96)0.9 ± 0.00.9 ± 0.00.9 ± 0.00.9 ± 0.0
Baseline VAS (n=27,75,42,120)79.6 ± 3.476.5 ± 2.276.8 ± 3.575.3 ± 1.8
Week 56 VAS (n=22,65,34,96)82.0 ± 2.582.3 ± 1.782.7 ± 2.783.8 ± 1.2
SecondaryMean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Week 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Week 24 Utility Score (n=269,269)0.1 ± 0.00.2 ± 0.0
Week 24 VAS (n=268, 271)5.3 ± 1.59.3 ± 1.4
SecondaryMean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Week 56 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Week 56 Utility Score0.0 ± 0.00.1 ± 0.0-0.0 ± 0.00.1 ± 0.0
Week 56 Visual Analogue Score-1.0 ± 1.64.2 ± 1.76.4 ± 3.86.4 ± 1.5
SecondaryMean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

Time frame:
Baseline and Week 24 (Period A)
Reported as:
Mean · score on a scale
Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)
score on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Mobility, Baseline (n=329,332)1.3 ± 0.01.3 ± 0.0
Mobility, Week 24 (n=270,274)1.2 ± 0.01.2 ± 0.0
Self-Care, Baseline (n=330,332)1.1 ± 0.01.1 ± 0.0
Self-Care, Week 24 (n=270,272)1.1 ± 0.01.0 ± 0.0
Usual Activities Baseline (n=330,332)1.4 ± 0.01.4 ± 0.0
Usual Activities Week 24 (n=270,273)1.2 ± 0.01.1 ± 0.0
Pain/Discomfort Baseline (n=330,332)1.8 ± 0.01.9 ± 0.0
Pain/Discomfort Week 24 (n=270,274)1.5 ± 0.01.4 ± 0.0
Anxiety/Depression Baseline (n=330,332)1.4 ± 0.01.4 ± 0.0
Anxiety/Depression Week 24 (n=270,274)1.3 ± 0.01.3 ± 0.0
SecondaryMean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").

Time frame:
Baseline and Week 56 (Period C)
Reported as:
Mean · score on a scale
Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)
score on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Baseline Mobility (n=27,75,42,120)1.2 ± 0.11.2 ± 0.01.1 ± 0.11.2 ± 0.0
Week 56 Mobility (n=22,65,34,96)1.2 ± 0.11.1 ± 0.01.1 ± 0.11.2 ± 0.0
Baseline Self-Care (n=27,75,42,120)1.1 ± 0.11.1 ± 0.01.0 ± 0.01.1 ± 0.0
Week 56 Self-Care (n=22,65,34,96)1.1 ± 0.11.0 ± 0.01.0 ± 0.01.0 ± 0.0
Baseline Usual Activities (n=27,75,42,120)1.3 ± 0.11.2 ± 0.11.1 ± 0.11.3 ± 0.0
Week 56 Usual Activities (n=22,65,34,96)1.1 ± 0.11.1 ± 0.01.1 ± 0.11.1 ± 0.0
Baseline Pain/Discomfort (n=27,75,42,120)1.5 ± 0.11.6 ± 0.11.3 ± 0.11.7 ± 0.1
Week 56 Pain/Discomfort (n=22,65,34,96)1.4 ± 0.11.5 ± 0.11.3 ± 0.11.4 ± 0.1
Baseline Anxiety/Depression (n=27,75,42,120)1.3 ± 0.11.3 ± 0.11.2 ± 0.11.3 ± 0.0
Week 56 Anxiety/Depression (n=22,65,34,96)1.2 ± 0.11.3 ± 0.11.2 ± 0.11.2 ± 0.0
SecondaryMean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-A defined as the last observation up to first dosing date in Period A.

Time frame:
Week 24 (Period A)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)
scores on a scaleCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Mobility (n=269,271)-0.1 ± 0.0-0.1 ± 0.0
Self-Care (n=270,269)0.0 ± 0.0-0.1 ± 0.0
Usual Activities (n=270,270)-0.1 ± 0.0-0.2 ± 0.0
Pain / Discomfort (n=270,271)-0.3 ± 0.0-0.5 ± 0.0
Anxiety / Depression (n=270,271)-0.1 ± 0.0-0.2 ± 0.0
SecondaryMean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-C defined as the last observation up to first dosing date in Period C.

Time frame:
Week 56 (Period C)
Reported as:
Mean · scores on a scale
Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)
scores on a scaleCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Mobility0.0 ± 0.1-0.0 ± 0.00.0 ± 0.0-0.0 ± 0.0
Self-Care0.0 ± 0.1-0.1 ± 0.00.0 ± 0.0-0.1 ± 0.0
Usual Activities-0.0 ± 0.0-0.1 ± 0.00.0 ± 0.0-0.2 ± 0.0
Pain / Discomfort0.0 ± 0.1-0.1 ± 0.10.0 ± 0.1-0.3 ± 0.1
Anxiety / Depression-0.1 ± 0.1-0.1 ± 0.10.1 ± 0.1-0.1 ± 0.1
SecondaryPercentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)
Time frame:
Weeks 4, 8, 16, and 24 (Period A)
Reported as:
Number · percentage of participants
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)
percentage of participantsCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)
Erythrodermic psoriasis0.00.6
Guttate psoriasis0.00.0
Pustular psoriasis0.00.3
SecondaryPercentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)
Time frame:
Weeks 4, 8, 12, and 16 (Period B)
Reported as:
Number · percentage of participants
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)
percentage of participantsCP-690,550 5 mg BID (Period B)Placebo for 5 mg CP-690,550 BID (Period B)CP-690,550 10 mg BID (Period B)Placebo for 10 mg CP-690,550 BID (Period B)
Erythrodermic psoriasis0.00.00.00.0
Guttate psoriasis0.00.00.00.8
Pustular psoriasis0.00.00.00.0
SecondaryPercentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)
Time frame:
Weeks 4, 8, and 16 (Period C)
Reported as:
Number · percentage of participants
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)
percentage of participantsCP-690,550 5 mg BID / CP-690,550 5 mg BIDPlacebo BID / CP-690,550 5 mg BIDCP-690,550 10 mg BID / CP-690,550 10 mg BIDPlacebo BID / CP-690,550 10 mg BID
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)0.00.00.00.0

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CP-690,550 5 mg BID (Period A)—6/218 (2.8%)101/218 (46.3%)
CP-690,550 10 mg BID (Period A)—9/157 (5.7%)94/157 (59.9%)
CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg—1/31 (3.2%)25/31 (80.6%)
CP-690,550 5 mg/Placebo/CP-690,550 5 mg—3/82 (3.7%)65/82 (79.3%)
CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg—4/45 (8.9%)41/45 (91.1%)
CP-690,550 10 mg / Placebo / CP-690,550 10 mg—4/133 (3%)108/133 (81.2%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mgCP-690,550 5 mg/Placebo/CP-690,550 5 mgCP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mgCP-690,550 10 mg / Placebo / CP-690,550 10 mg
Chest painGeneral disorders0/2180/1571/310/820/450/133
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/2180/1571/310/820/450/133
BronchitisInfections and infestations0/2180/1570/310/821/450/133
Peritonsillar abscessInfections and infestations0/2180/1570/310/821/450/133
Traumatic lung injuryInjury, poisoning and procedural complications0/2180/1570/310/821/450/133
DepressionPsychiatric disorders0/2180/1570/310/821/450/133
Erythrodermic psoriasisSkin and subcutaneous tissue disorders0/2182/1570/310/820/450/133
GoitreEndocrine disorders0/2180/1570/311/820/450/133
HypomaniaPsychiatric disorders0/2180/1570/311/820/450/133
NephrolithiasisRenal and urinary disorders0/2180/1570/311/820/450/133
Most frequent other events
Showing 10 of 144
Most frequent other events
EventCP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mgCP-690,550 5 mg/Placebo/CP-690,550 5 mgCP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mgCP-690,550 10 mg / Placebo / CP-690,550 10 mg
Blood creatine phosphokinase increasedInvestigations10/2185/1571/316/8212/4514/133
NasopharyngitisInfections and infestations18/21815/1573/3115/828/4523/133
Upper respiratory tract infectionInfections and infestations9/2187/1572/3114/825/4518/133
Oropharyngeal painRespiratory, thoracic and mediastinal disorders5/2183/1575/311/823/452/133
HeadacheNervous system disorders6/2186/1572/315/824/4517/133
DiarrhoeaGastrointestinal disorders7/2185/1570/313/824/458/133
Urinary tract infectionInfections and infestations7/2185/1571/316/824/459/133
Blood cholesterol increasedInvestigations3/2183/1570/312/824/454/133
Low density lipoprotein increasedInvestigations0/2181/1570/311/824/451/133
HypercholesterolaemiaMetabolism and nutrition disorders0/2187/1571/310/824/454/133

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized at baseline and received at least one dose of the randomized investigational drug (CP-690,550 5 mg BID or 10 mg BID) during Period A.

Age, Continuous
Age, Continuous(years)CP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mgCP-690,550 5 mg/Placebo/CP-690,550 5 mgCP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mgCP-690,550 10 mg / Placebo / CP-690,550 10 mgTotal
Mean42.8 ± 13.045.6 ± 12.644.3 ± 13.045.2 ± 13.448.5 ± 14.846.1 ± 13.444.9 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)CP-690,550 5 mg BID (Period A)CP-690,550 10 mg BID (Period A)CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mgCP-690,550 5 mg/Placebo/CP-690,550 5 mgCP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mgCP-690,550 10 mg / Placebo / CP-690,550 10 mgTotal
Female655011271144208
Male15310720553489458
08

Study locations

87 sites
  • Horizon Research Group, Inc.
    Mobile, Alabama 36608, United States
  • Radiant Research, Inc.
    Tucson, Arizona 85710, United States
  • Center for Dermatology Clinical Research, Inc.
    Fremont, California 94538, United States
  • Associates In Research, Inc.
    Fresno, California 93720, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Expresscare Medical
    Los Angeles, California 90045, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • University of California San Francisco
    San Francisco, California 94118, United States
  • Longmont Clinic, PC
    Longmont, Colorado 80501, United States
  • New England Research Associates, LLC
    Trumbull, Connecticut 06611, United States
  • Florida Academic Dermatology Center
    Miami, Florida 33136, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Altman Dermatology Associates
    Arlington Heights, Illinois 60005, United States
  • Springfield Clinic, LLP
    Springfield, Illinois 62703, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Deaconess Clinic Downtown
    Evansville, Indiana 47713, United States
  • DMIA
    Louisville, Kentucky 40207, United States
  • DermResearch, PLLC
    Louisville, Kentucky 40217, United States
  • Quest Diagnostics
    Louisville, Kentucky 40217, United States
  • Northeast Dermatology Associates
    Beverly, Massachusetts 01915, United States
  • ActivMed Practices and Research, Inc.
    Haverhill, Massachusetts 01830, United States
  • Michigan Center for Research Corporation dba Michigan Center for Skin Care Research
    Clinton Township, Michigan 48038, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Dermatology Associates
    Wilmington, North Carolina 28401, United States
  • New Hanover Medical Group, PA
    Wilmington, North Carolina 28401, United States
  • New Hanover Medical Research
    Wilmington, North Carolina 28401, United States
  • PMG Research of Wilmington LLC
    Wilmington, North Carolina 28401, United States
  • Piedmont Imaging
    Winston-Salem, North Carolina 27103, United States
  • Piedmont Medical Research
    Winston-Salem, North Carolina 27103, United States
  • Triad Dermatology, PA
    Winston-Salem, North Carolina 27103, United States
  • Jewish Hospital
    Cincinnati, Ohio 45236, United States
  • Radiant Research, Inc.
    Cincinnati, Ohio 45249, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Oregon Medical Research Center, PC
    Portland, Oregon 97223, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical Research South, LLC
    Charleston, South Carolina 29407, United States
  • Office of Marta T. Hampton, MD
    Charleston, South Carolina 29407, United States
  • Dermatology & Laser Center of Charleston
    Charleston, South Carolina 29414, United States
  • Office of John Michael Humeniuk, MD
    Greer, South Carolina 29650, United States
  • Radiant Research, Inc.
    Greer, South Carolina 29651, United States
  • Dermatology Research Associates
    Nashville, Tennessee 37203, United States
  • Office of Stephen Miller, MD, PA
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Mountain State Clinical Research
    Clarksburg, West Virginia 26301, United States
  • Centro de Investigaciones Dermatologicas
    Ciudad Autonoma de Buenos Aires, C1114aap, Argentina
  • Centro de Investigaciones Dermatologicas
    Ciudad Autonoma de Buenos Aires, C1114AAP, Argentina
  • IMAI (Instituto Medico de Asistencia e Investigaciones)
    Ciudad Autonoma de Buenos Aires, C1425AWC, Argentina
  • Dr. Glenn & Partners
    Kogarah, New South Wales 2217, Australia
  • Premier Dermatology
    Kogarah, New South Wales 2217, Australia
  • Skin and Cancer Foundation
    Carlton, Victoria 3053, Australia
  • Uniradiology
    Carlton, Victoria 3053, Australia
  • Emeritus Research
    Malvern East, Victoria 3145, Australia
  • Malvern Diagnostic Imaging
    Malvern, Victoria 3144, Australia
  • Instituto de Dermatologia e Est�ca do Brasil LTDA - IDERJ
    Rio de Janeiro, RJ 22470-220, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
    Sao Paulo, SP 05403-900, Brazil
  • Universitetska Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Dr Georgi Stranski- Pleven
    Pleven, 5800, Bulgaria
  • Tsentar za kozhno-venericheski zaboliavania� EOOD
    Sofia, 1404, Bulgaria
  • Mnogoprofilna Bolnitsa Za Aktivno Lechenie- Tokuda Bolnitsa Sofia- Sofia
    Sofia, 1407, Bulgaria
  • Universitetska mnogoprofilna bolnitsa za aktivno lechenie- Alexandrovska- Sofia
    Sofia, 1431, Bulgaria
  • MBAL na Voennomeditsinska akademia- Sofia
    Sofia, 1606, Bulgaria
  • Derm Research @ 888 Inc.
    Vancouver, British Columbia V5Z 3Y1, Canada
  • UBC Department of Dermatology and Skin Science
    Vancouver, British Columbia V5Z 4E8, Canada
  • Nexus Clinical Research
    Saint John's, Newfoundland and Labrador A1A 5E8, Canada
  • NewLab Clinical Research Inc.
    St. John's, Newfoundland and Labrador A1C 2H5, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1V6, Canada
  • Windsor Clinical Research
    Windsor, Ontario N8W 5L7, Canada
  • Innovaderm Research Inc
    Montreal, Quebec H2K 4L5, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Quebec, G1V 4X7, Canada
  • Department of Dermatology, Aarhus University Hospital
    Aarhus C, 8000, Denmark
  • Gentofte Hospital
    Hellerup, 2900, Denmark
  • Hudklinikken
    Svendborg, 5700, Denmark
  • Tampere University Hospital, Department of Dermatology and Venreology
    Tampere, 33521, Finland
  • Dermatology Department, Andreas Sygros Hospital
    Aathens, 16121, Greece
  • University Hospital of Ioannina/Dermatology Department
    Ioannina, 45500, Greece
  • "Papageorgiou" General Hospital / B' Dermatology and Venereology Clinic of University of Thessalonik
    Thessaloniki, 56403, Greece
  • PT & R
    Beek, 6191 JW, Netherlands
  • Univerzitna Nemocnica, Bratislava
    Bratislava, 813 69, Slovakia
  • Fakultna Nemocnica Trnava
    Trnava, 917 75, Slovakia
  • Whipps Cross University Hospital, Department of Dermatology
    London, Leytonstone E11 1NR, United Kingdom
  • Department of Dermatology
    Nuneaton, Warwickshire CV10 7DJ, United Kingdom
  • Salford Royal NHS Foundation Trust
    Manchester, M6 8HD, United Kingdom
09

References and documents

Publications

  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, Bachinsky M, Rottinghaus ST, Tan H, Proulx J, Valdez H, Gupta P, Mallbris L, Wolk R. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015;172(5):1395-406. doi: 10.1111/bjd.13551. Epub 2015 Apr 2. PubMed 25418186 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2010
First posted
Aug 23, 2010
Start
Sep 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Jun 4, 2014
Last update
Dec 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01186744
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 23, 2010
Start date
Sep 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Jun 4, 2014
Last update
Dec 26, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion